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µ    Micro (10-6) 
ADP    Adenosine diphosphate 
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APC   Adenomatosis polyposis coli or antigen-presenting cell 
ATM  Serine-protein kinase ATM;  
alternative name: Ataxia telangiectasia mutated 
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ATR  Serine/threonine-protein kinase ATR;  
alternative name: Ataxia telangiectasia and Rad3-related protein  
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BRAF  B-Raf proto-oncogene, serine/threonine kinase;  
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CD   Cluster of differentiation 
CDK   Cyclin-dependent kinases 
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ELISA   Enzyme-linked immunosorbent assay 
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HDAC   Histone deacetylase 
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mDCs    Myeloid DCs 
MDSC   Myeloid-derived suppressor cell 
min   Minute 
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Zusammenfassung 
Die Strahlentherapie ist ein essentieller Bestandteil der multimodalen Behandlung von 
Krebserkrankungen. Ein Versagen dieser Therapieform wird mit intrinsischer Strahlenresistenz 
in Verbindung gebracht. Deshalb ist der Fokus der vorliegenden Arbeit die Identifizierung von 
geeigneten Biomarkern für intrinsische Strahlenresistenz und deren pharmakologische 
Nutzung, um die therapeutische Breite der Strahlentherapie zu verbessern. 
Die Effizienz der Behandlung von Weichteilsarkomen mittels Strahlentherapie ist aufgrund 
von Unterschieden in der Strahlensensibilität verschiedener Sarkoma-Subtypen leider 
eingeschränkt. In der vorliegenden Arbeit wurden systematische Analysen der intrinsischen 
Strahlenresistenz verschiedener Weichteilsarkom-Zelllinien durchgeführt, und anhand einer 
Hauptkomponentenanalyse von Klonogenitätsdaten wurden Radioresistenz-Scores extrahiert. 
In Korrelationsanalysen dieser Radioresistenz-Scores mit Transkriptomprofilen von DNA-
Schadensreparatur-Regulatoren zeigten starke positive Korrelationen für die mRNA-
Expressionslevels des molekularen Chaperons Hitzeschockprotein 90 (HSP90) und seiner 
Klientenproteine ATM, ATR und NBS1. Dadurch wurden diese Kandidaten als potentielle 
Biomarker für strahlenresistente, aggressive Weichteilsarkome identifiziert. Untersuchungen 
des Datensatzes der Weichteilsarkomkohorte des Cancer Genome Atlas (TCGA) bestätigten 
eine gesteigerte Expression dieser Kandidaten-Biomarker in Tumorproben von Patienten mit 
schlechterem klinischem Verlauf und besonders kurzem Gesamtüberleben. Die Inhibition von 
HSP90 und die damit einhergehende Beeinträchtigung seiner Klientenproteine (u.a. ATM, ATR 
und NBS1) könnte daher ein vielversprechender Ansatz zur zielgerichteten Modulation der 
intrinsischen Strahlenresistenz sein. In der vorliegenden Arbeit wurde der neue Pochoxim-
basierte Wirkstoff NW457 für die Inhibition von HSP90 verwendet. Tatsächlich reichten 
niedrige nanomolare Konzentrationen von NW457 aus, um strahlenresistente Weichteilsarkom-
Zelllinien gegenüber ionisierender Strahlung in vitro zu sensibilisieren. NW457 erhöhte den 
strahleninduzierten klonogenen Zelltod begleitet von einer Hemmung bzw. Verzögerung der 
DNA-Schadensreparatur. Während strahlungsvermittelte Apoptose und Nekrose in diesem 
Konzentrationsbereich unbeeinflusst waren, scheint die zelluläre Seneszenz in der NW457-
vermittelten Strahlensensibilisierung eine Rolle zu spielen. Hier sind weitere mechanistische 
Untersuchungen erforderlich und geplant. 
Die Suche nach strahlensensibilisierenden Wirkstoffen ist auch für die Behandlung des 
kolorektalen Karzinoms von großem Interesse, da die Anwendung ionisierender Strahlung 
aufgrund der hohen Darmmobilität und der relativen Strahlensensitivität des umliegenden 
Normalgewebes Schwierigkeiten in dieser Entität mit sich bringt. Daher wurde das 
strahlensensibilisierende Potential des neuen HSP90-Inhibitors NW457 auch in dieser 
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Krebsentität analysiert. Tatsächlich sensibilisierte NW457 kolorektale Karzinom-Zelllinien 
wirksam gegenüber ionisierender Strahlung in vitro und in vivo. Die durch eine Inhibition von 
HSP90 vermittelte Beeinträchtigung der DNA-Schadensreparatur resultierte in einer 
signifikanten Verminderung des klonogenen Überlebens nach Bestrahlung – im Wesentlichen 
unabhängig vom p53- und BAX-Status. Hohe Konzentrationen von NW457 in Kombination 
mit Bestrahlung induzierten Apoptose und förderten den Übergang zur sekundären Nekrose 
durch BAX-abhängige und -unabhängige Mechanismen während p53 in dem Szenario 
vernachlässigbar zu sein scheint. In einem murinen syngenen, heterotopen kolorektalen 
Tumormodel verbesserte NW457 die durch Bestrahlung erreichte Tumorkontrolle signifikant 
und zeigte eine reduzierte Hepatotoxizität im Vergleich zu HSP90-Inhibitoren der ersten und 
zweiten Generation. Neben seiner strahlensensibilisierenden Wirkung beeinflusste NW457 die 
Art des strahleninduzierten kolorektalen Tumorzelltods und führte zum verstärkten bzw. 
beschleunigten Auftreten von Sekundärnekrose. Die damit verbundene Freisetzung von 
immunogenen DAMPs (damage-associated molecular patterns) und die Rekrutierung von 
monozytären Zellen in vitro und in vivo weisen auf eine gesteigerte Tumorimmunogenität hin, 
und es bleibt zu klären, inwiefern diese Mechanismen einen Beitrag zur beobachteten 
verbesserten Tumorkontrolle leisten. 
Zusammenfassend lässt sich festhalten, dass der neue Pochoxim-basierte HSP90 Inhibitor 
NW457 die therapeutische Breite der Strahlentherapie steigern kann und gleichzeitig die 
Tumorimmunogenität erhöht. Demzufolge erscheint dieser Ansatz als eine vielversprechende 
Kombinationsstrategie für die Strahlentherapie resistenter, aggressiver Weichteilsarkome und 
kolorektaler Karzinome. 
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Abstract 
Radiotherapy is an essential part of multimodal anti-cancer treatment. Failure of this therapy 
is considered to be associated with intrinsic radioresistance. Therefore, this study focuses on 
the identification of potential biomarkers of intrinsic radioresistance and their pharmacological 
exploitation in order to improve the therapeutic width of radiotherapy.  
For soft tissue sarcomas, the efficacy of radiotherapy is limited due to strong differences in 
radiosensitivity of distinct sarcoma subtypes. In the present study, systematic analyses of the 
intrinsic radioresistance of a panel of soft tissue sarcoma cell lines were performed, and 
quantitative scores of radioresistance were extracted by principal component analysis. 
Correlation analyses of these radioresistance scores with transcriptomic profiling data of DNA 
damage response regulators revealed strong positive correlations for the mRNA expression 
levels of the molecular chaperone heat shock protein 90 (HSP90) and its client proteins ATM, 
ATR, and NBS1, thereby identifying these candidates as potential biomarkers for radioresistant, 
aggressive soft tissue sarcomas. Query of the soft tissue sarcoma cohort of the Cancer Genome 
Atlas (TCGA) database displayed upregulated expression of these candidate biomarkers in 
tumor samples of patients with dismal clinical outcome and particularly poor overall survival. 
Thus, HSP90 inhibition and concomitant client protein deprivation could represent a promising 
approach to target intrinsic radioresistance. In the present study, the novel pochoxime-based 
compound NW457 was utilized for HSP90 inhibition. Indeed, low nanomolar concentrations 
of NW457 potently sensitized radioresistant soft tissue sarcoma cell lines towards ionizing 
radiation in vitro. NW457 increased irradiation-induced clonogenic cell death accompanied by 
impairment of the DNA damage response. Whereas irradiation-induced apoptosis and necrosis 
virtually remained unaffected, cellular senescence appears to be involved in NW457-mediated 
radiosensitization. Further studies elucidating the underlying mechanisms in greater depth are 
necessary and planned.  
Finding radiosensitizing agents is also of high interest for the treatment of colorectal cancers, 
since application of ionizing radiation can be difficult in this entity due to the high degree of 
mobility of the large intestine and considerable radiosensitivity of the surrounding normal 
tissue. Therefore, the radiosensitizing potential of the novel HSP90 inhibitor NW457 was also 
analyzed in models of this cancer entity. Indeed, NW457 potently sensitized colorectal cancer 
cells towards ionizing radiation in vitro and in vivo. HSP90 inhibitor-mediated impairment of 
the DNA damage response resulted in significantly decreased clonogenic survival upon 
irradiation – virtually irrespective of the p53 and BAX status. Higher concentrations of NW457 
in combination with irradiation induced apoptosis and accelerated the transition into secondary 
necrosis by BAX-dependent and -independent mechanisms, whereas p53 appears to be 
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dispensable in this scenario. In a murine syngeneic, heterotopic colorectal cancer model, 
NW457 potently improved irradiation-mediated tumor control and displayed reduced 
hepatotoxicity compared to HSP90 inhibitors of the first and second generation. Apart from its 
radiosensitizing effects, NW457 affected the mode of irradiation-induced colorectal cancer cell 
death and favored the onset of secondary necrosis. The concomitant release of immunogenic 
DAMPs (damage-associated molecular patterns) and the attraction of monocytes in vitro and in 
vivo are indicative for enhanced tumor immunogenicity, and it remains to be elucidated how 
far these mechanisms contribute to the observed improvement in tumor control. 
In summary, the novel pochoxime-based HSP90 inhibitor NW457 improves the therapeutic 
width of radiotherapy and enforces tumor immunogenicity. Hence, this approach appears as a 
promising combined modality strategy for radiotherapy of resistant, aggressive soft tissue 
sarcomas and colorectal cancers. 
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1 Introduction 
Cancer is the second leading cause of death worldwide. In 2012, 14.1 million new cases 
were diagnosed, with the most common entities being cancers of the lung, breast, and 
colorectum. In terms of mortality, cancers of the lung, liver, stomach, and colorectum 
account for the majority of all cases (i.e. 8.2 million deaths in 2012) (Ferlay et al., 2015). 
For the future, increasing incidences are predicted due to the aging world population and the 
adoption of cancer-causing westernized lifestyles within economically developing countries 
(i.e. unhealthy diet and less physical activity) (Bray et al., 2012; Jemal et al., 2011). Although 
there are genetic predispositions, inherited factors account for the minority of cancers 
(approximately 5%-10%) (Anand et al., 2008). 
Cancer is a disease of multicellular organisms that can arise from almost every tissue in 
the body, and more than 100 different forms are currently known (Hanahan and Weinberg, 
2000). The well-acknowledged multi-step model of cancerogenesis describes the 
transformation of a normal cell into a malignant cell by stepwise accumulation of somatic 
mutations in proto-oncogenes and/or tumor suppressor genes and subsequent clonal 
selection, analogous to Darwinian evolution (Kinzler and Vogelstein, 1996; Nowell, 1976; 
Vogelstein et al., 1988; Vogelstein and Kinzler, 1993). During this process, whose duration 
and molecular details are distinct for different cancer entities, cancer cells acquire a set of 
crucial capabilities, the so-called hallmarks of cancer. The first six hallmarks of cancer that 
were originally defined by Hanahan and Weinberg in 2000 comprise features allowing tumor 
growth, survival, and formation of metastasis: ‘sustaining proliferative signaling’, ‘evading 
growth suppressors’, ‘resisting cell death’, ‘enabling replicative immortality’, ‘inducing 
angiogenesis’, and ‘activating invasion and metastasis’ (Hanahan and Weinberg, 2011). In 
2011, two further hallmarks and two enabling characteristics crucial to the acquisition of the 
hallmarks were defined: The enabling characteristic ‘genome instability and mutation’ 
favors the accumulation of mutations and the emergence of tumor cell variants with acquired 
hallmarks and corresponding survival benefits, and ‘tumor-promoting inflammation’ refers 
to an immune-mediated, inflammatory, tumor-promoting microenvironment that is enriched 
in growth, survival, and proangiogenic factors. The two new hallmarks encompassed 
‘deregulating cellular energetics’ necessary to fulfil the energetic and anabolic requirements 
of the growing tumor and ‘avoiding immune destruction’ describing the observation that 
most clinically manifest tumors are poorly immunogenic and have managed to escape the 
immune system (Hanahan and Weinberg, 2011). This poorly immunogenic status is 
established in a process known as cancer-immunoediting consisting of three steps: 
elimination, equilibrium, and escape (Dunn et al., 2006; Schreiber et al., 2011). During the 
elimination phase, the immune system initially attacks and kills cells of the growing tumor. 
INTRODUCTION 
2 
However, individual tumor cells can survive the elimination phase because they have 
acquired non-immunogenic features and thus have growth advantages (equilibrium phase). 
Finally, the tumor cell variants that have been selected in the equilibrium phase successfully 
evade the immune attack and give rise to a poorly immunogenic tumor with a high degree 
of resistance against immune detection (escape phase). 
1.1 Soft Tissue Sarcoma 
Soft tissue sarcomas (STSs) are rare, heterogeneous tumors accounting for about 1% of 
all adult and 8% of all pediatric cancers in children <15 years of age (Linch et al., 2014; 
Sangkhathat, 2015). These malignancies are of mesenchymal, non-epithelial origin and are 
the most frequent among all sarcomas. The majority of STSs occur in the extremities and 
the abdomen (Clark et al., 2005; Demetri et al., 2010). More than 50 histological subtypes 
are defined, including rhabdomyosarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, 
synovial sarcoma, and gastrointestinal stromal tumors (GISTs) arising from skeletal muscle, 
smooth muscle, fat, fibrous tissue, tissue around the joints, or the gastrointestinal tract, 
respectively (Clark et al., 2005; Fletcher, 2014). Rhabdomyosarcoma is the most common 
STS in children (Sangkhathat, 2015). The majority of STSs are sporadic. Risk factors for 
STS development are environmental influences (e.g. exposure to vinyl chloride, ionizing 
radiation (IR)), viral infections (e.g. kaposi´s sarcoma, leiomyosarcoma), and genetic 
predisposition syndromes, such as the Li-Fraumeni syndrome in which a germline mutation 
of the tumor suppressor tumor protein p53 (TP53) is associated with occurrence of 
rhabdomyosarcoma (Clark et al., 2005; Thomas and Ballinger, 2015). From a genetic point 
of view, STSs can be categorized into two groups with different pathogenesis-driving genetic 
aberrations. The first comprises malignancies with simple karyotypes and distinct 
translocations generating fusion genes or specific oncogenic mutations, respectively. The 
second group contains tumors with complex karyotypes characterized by numerous 
chromosomal aberrations due to a high degree of genome instability (Bridge, 2014; Taylor 
et al., 2011). 
The standard treatment for non-metastatic, localized STSs comprises surgery in 
combination with adjuvant (post-operative) radiotherapy (RT) to improve the local control 
rate. In cases in which the feasibility of surgery is questionable, neoadjuvant (pre-operative) 
RT is implemented in order to reduce the tumor burden prior to resection. For unresectable 
disease, RT can be administrated as a primary treatment. Multimodal treatment with 
chemotherapy (e.g. doxorubicin, ifosfamide), RT, and surgery shows efficacy in patients 
with advanced disease (Demetri et al., 2010; Group, 2014; von Mehren et al., 2014). The 
five-year overall survival rates of STSs vary between tumor stages, declining from 
approximately 90% for initial stages to 10%-20% for advanced stages. Local recurrence and 
INTRODUCTION 
3 
metastasis, typically to the lungs, are the major underlying reasons (Clark et al., 2005; Kneisl 
et al., 2014). Since pathogenesis of STSs is driven by specific genetic aberrations, molecular 
targeting of protein kinases (e.g. serine/threonine-protein kinase mTOR (mTOR), vascular 
endothelial growth factor receptor (VEGFR)) or histone deacetylases (HDACs) has been 
explored to improve treatment outcome. So far, the most effective targeted drug is the 
tyrosine kinase inhibitor imatinib that has been approved for the treatment of GISTs and 
dermatofibrosarcoma protuberans (DFSP). 80% of GIST patients respond to imatinib – at 
least partially – when carrying activating mutations in the KIT proto-oncogene receptor 
tyrosine kinase (KIT). In DFSP, imatinib inhibits platelet derived growth factor receptor 
(PDGFR), which is overexpressed due to gene fusion with the collagen type I alpha 1 chain 
(COL1A1) promotor (Demicco et al., 2012; Taylor et al., 2011). Since treatment options 
especially for advanced, recurrent, and metastatic STSs are limited, novel and effective 
molecularly targeted therapies as well as immunotherapies are of high clinical interest. In 
this regard, the heterogeneity of STS subtypes represents a crucial and challenging factor 
demanding for rational and adequate patient stratification (Tseng et al., 2014). 
1.2 Colorectal Cancer 
Colorectal cancer (CRC) is the third most common cancer worldwide accounting for more 
than one million new diagnoses per year (about 10% of all new cancer cases). In terms of 
mortality, CRC is the fourth most common cause of cancer-related deaths with 
approximately 600.000 cases per year (Ferlay et al., 2015). CRCs originate from epithelial 
cells of the colon or rectum, usually beginning as benign adenomatous polyps before 
transforming into invasive, malignant cancers (Markowitz and Bertagnolli, 2009). The 
development of CRCs follows the classical multi-step model of carcinogenesis involving the 
gradual accumulation of genetic and epigenetic alterations over years and decades. In fact, 
the multi-step model was established at this cancer entity (Fearon and Vogelstein, 1990; 
Kinzler and Vogelstein, 1996; Vogelstein et al., 1988; Vogelstein and Kinzler, 1993). The 
majority of CRCs are sporadic (70%-80%) and not inherited. Risk factors include increasing 
age, previous polyps, male sex, and environmental factors comprising high-fat diet, red meat 
consumption, obesity, elevated consumption of alcohol, smoking, and a sedentary lifestyle 
(Binefa et al., 2014). Inflammatory bowel diseases, such as Crohn´s disease and ulcerative 
colitis, strongly increase the risk of colitis-associated cancer and thus are considered as 
precancerosis (Garg and Loftus, 2016). Rare inherited forms of CRCs are familial 
adenomatous polyposis, MYH-associated polyposis, and Lynch syndrome (hereditary non-
polyposis colorectal cancer) (Binefa et al., 2014; Cunningham et al., 2010). CRCs are 
classified into three phenotypes with different potentially overlapping genetic instabilities. 
The most common phenotype has a chromosomal instability in which amplifications or 
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translocations of chromosomes contribute to aneuploidy. Chromosomal instability is 
associated with accumulation of mutations in proto-oncogenes (e.g. KRAS proto-oncogene, 
GTPase (KRAS), B-Raf proto-oncogene, serine/threonine kinase (BRAF)) and tumor 
suppressor genes (e.g. adenomatosis polyposis coli (APC), TP53, SMAD4). The 
microsatellite instability phenotype accumulates errors during DNA replication in short 
tandem repeat sequences (microsatellites) due to mutations in replication mediating genes 
(e.g. MLH1, MSH2, MSH6). The CpG island methylator phenotype exhibits 
hypermethylation of CpG islands, which is a mechanism of gene silencing (Aghagolzadeh 
and Radpour, 2016; Bogaert and Prenen, 2014; Markowitz and Bertagnolli, 2009; Walther 
et al., 2009).  
Surgery is the main treatment option for CRC, mostly with curative intention in case of 
initial stages. For more advanced stages, surgery is complemented with adjuvant or 
neoadjuvant chemotherapy, RT, or radiochemotherapy, respectively. Different regimes of 5-
fluorouracil, its pro-drug capecitabine, oxaliplatin, folinic acid, and irinotecan are used for 
systemic chemotherapy (Binefa et al., 2014; Cunningham et al., 2010). Whereas RT is 
commonly employed as treatment modality for rectal cancer, its application in colon cancer 
is largely restricted to high-risk cases due to the relevant degree of mobility within the colon 
and the resulting radiation toxicity to surrounding organs (Glimelius, 2002; van de Velde et 
al., 2014; Willett et al., 1999). Disseminated CRCs, which are characterized by typical 
metastasis formation in liver and lungs, require multimodal treatment with surgery, 
chemotherapy, RT, and targeted therapies against VEGFR and/or epidermal growth factor 
receptor (EGFR) (Ahn et al., 2016; Binefa et al., 2014). Mutations in the proto-oncogenes 
KRAS (in up to 50% of all CRCs) and BRAF (in approximately 10% of CRCs) encoding for 
downstream mediators in the EGFR signaling pathway represent contraindications for 
EGFR-directed therapies. These mutations lead to constitutive activation of the GTPase 
KRas (KRAS) and the serine/threonine-protein kinase B-raf, thereby inducing tumor-
promoting signaling of mitogen-activated protein kinase (MAPK)- and phosphatidylinositol 
3-kinase (PI3K) pathway irrespective of EGFR blockade (Bazan et al., 2005; Binefa et al., 
2014; Cunningham et al., 2010). In addition, inactivating mutations in the tumor suppressor 
TP53 (in up to 50% of all CRCs) encoding for the central cell cycle regulator and 
transcription factor cellular tumor antigen p53 (p53) have been reported to associate with 
poorer prognosis (Bazan et al., 2005; Iacopetta et al., 2006; Russo et al., 2005).  
Despite a decline in CRC deaths over the last decades as a result of better prevention, 
early detection, and more elaborate treatment, the five-year survival rates still range from 
75%-90% for initial stages to less than 15% for advanced stages (Binefa et al., 2014). 
Advances in classifying CRC phenotypes and the associated cell populations and/or 
mechanisms mediating therapy resistance in greater depth as well as the development of 
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novel therapy strategies will hopefully contribute to further improve CRC treatment in the 
future. 
1.3 Radiotherapy: A Central Cornerstone of Cancer Treatment 
RT is one of the cornerstones of cancer treatment besides surgery and systemic 
chemotherapy. The medical application of IR improves tumor control and prolongs disease-
free and overall patient survival. More than 60% of all cancer patients receive RT at one 
point during their treatment, and various settings ranging from definitive to multimodal 
strategies, including neoadjuvant and adjuvant as well as palliative settings, are in clinical 
use (Orth et al., 2014). Implementation of RT varies according to tumor type, size, and stage. 
Conventionally fractionated RT comprises five daily fractions of 1.8-2 Gy per week up to a 
total dose of 45-70 Gy. For certain cancer entities, hypofractionation regimes with fewer and 
larger fractions are employed (Lauber et al., 2015). For instance, neoadjuvant RT with a 
daily dose of 5 Gy in 5 fractions is used in localized rectal cancer (Chen et al., 2015; van de 
Velde et al., 2014). In breast cancer, ongoing clinical trials will clarify if higher doses up to 
5 Gy per fraction in comparison to the commonly applied 2.66 Gy will define new 
alternatives. In case of ablative RT, such as stereotactic body RT, intraoperative RT, or 
brachytherapy, reduction of the fraction number is escalated to 1-5 high doses of more than 
10 Gy (Lauber et al., 2015).  
The aim of RT is to eradicate the tumor, while sparing the normal surrounding tissue. 
State-of-the-art RT comprises photon irradiation with intensity-modulated radiation therapy 
(IMRT) and image-guided radiation therapy (IGRT). These modern treatment technologies 
facilitate advanced precision treatment planning and image-guided administration of target 
volumes in order to achieve improved accuracy and to spare organs at risk. With the advent 
of new irradiation qualities, including protons and heavy ions, this preciseness has been 
brought to an even higher level (Baumann et al., 2016). However, due to high investment 
costs, the clinical availability of proton and heavy ion therapy remains largely limited. 
1.3.1 Molecular Responses to Ionizing Radiation 
The cytotoxic effects of IR derive from direct or indirect deoxyribonucleic acid (DNA) 
damage, with DNA double-strand breaks (DSBs) being the most lethal lesions. In order to 
guarantee genomic integrity, a plethora of sophisticated DNA repair mechanisms – termed 
DNA damage response (DDR) – have emerged. Upon DNA damage, the DDR orchestrates 
activation of cell cycle checkpoints, recruitment as well as activation of DNA repair proteins, 
and finally the repair of the damage. The success of DNA repair decides over cell survival 
or death, respectively (Begg et al., 2011; Roos et al., 2016). In principle, RT takes advantage 
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of the higher DNA repair capacity of normal cells in comparison to malignant cells, thereby 
aiming at abrogation of clonogenic survival and induction of cell death in the latter. 
1.3.1.1 DNA Damage Response 
DNA double-strand breaks, the most severe type of damage caused by IR, are repaired 
via two different pathways: Non-homologous end joining (NHEJ) or homologous 
recombination (HR) repair, respectively. Although NHEJ is highly error-prone due to 
ligation of the ends of two nearby broken DNA sequences, this mechanism can rapidly 
restore the majority of IR-induced DSBs during all phases of the cell cycle. In contrast, HR 
Figure 1 The DNA damage response.  
IR causes DNA damage that can be repaired via the DDR. A plethora of regulators 
detect, mediate, and eliminate DNA damage. The success of DNA repair determines 
cell proliferation, cellular senescence, and/or cell death. MRN complex, MRE11-
RAD50-NBS1 complex; RPA, replication protein A; ATM, serine-protein kinase 
ATM; ATR, serine/threonine-protein kinase ATR; ATRIP, ATR-interacting protein; 
RAD9, RAD9-RAD1-HUS1 complex; H2AX, histone H2AX; BRCA1, breast 
cancer type 1 susceptibility protein; 53BP1, tumor suppressor p53-binding protein 
1; MDC1, mediator of DNA damage checkpoint protein 1; TOPBP1, DNA 
topoisomerase 2-binding protein 1; p53, cellular tumor antigen p53; CDC25, cell 
division cycle 25. Adapted by permission from Macmillan Publishers Ltd: Nature 
Reviews Cancer (Sulli et al., 2012), copyright (2012). 
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is a highly accurate DNA repair mechanism as it uses the sister chromatid as template. HR 
repairs the minority of DSBs and is restricted to S- and G2-phase of the cell cycle, when 
sister chromatids are available (Begg et al., 2011; Curtin, 2012; Maier et al., 2015). DSBs 
are recognized by the MRE11-RAD50-NBS1 (MRN) complex that recruits and activates the 
central protein kinase serine-protein kinase ATM (ATM) (Figure 1). Subsequently, ATM 
phosphorylates histone H2AX (γH2AX) that, in turn, recruits multiple DNA repair factors. 
Single-stranded DNA resulting from DSB strand resection is recognized by replication 
protein A (RPA) that recruits and activates the next protein kinase within the cascade, 
serine/threonine-protein kinase ATR (ATR). ATM and ATR, together with their 
downstream protein kinases, serine/threonine-protein kinase Chk1 and Chk2 (CHK1 and 
CHK2), phosphorylate and activate various effector proteins, such as the central tumor-
suppressor protein p53 (Sengupta and Harris, 2005; Sulli et al., 2012). Phosphorylation of 
p53 leads to disruption of its interaction with the E3 ubiquitin-protein ligase Mdm2 
(MDM2), which under normal conditions mediates p53's continuous proteasomal 
degradation. Stabilized p53 and other effector proteins trigger transient or permanent cell 
cycle arrest as well as cell death (Ciccia and Elledge, 2010; Maier et al., 2015; Sengupta and 
Harris, 2005).  
1.3.1.2 Irradiation-induced Forms of Cell Death and Cellular Senescence 
In response to excessive, unrepaired DNA damage, different forms of cell death as well 
as cellular senescence can be induced – depending on the cellular origin, the genetic 
background, and the functionality of cell cycle checkpoints (Figure 2) (Lauber et al., 2012; 
Roos et al., 2016). Proliferating cells of the hematopoietic system, including lymphoma and 
leukemia, predominantly undergo apoptotic cell death (Eriksson and Stigbrand, 2010). 
Characteristic features of apoptosis include cellular shrinkage, membrane blebbing, 
exposure of the phospholipid phosphatidylserine, condensation of chromatin, and nuclear 
fragmentation (Taylor et al., 2008). Importantly, the plasma membrane stays intact during 
apoptosis. However, if apoptotic cells are not timely engulfed by surrounding cells or 
professional phagocytes, including macrophages and dendritic cells (DCs), they transit into 
post-apoptotic, secondary necrosis, and the plasma membrane disintegrates (Silva, 2010). 
IR stimulates apoptosis preferentially via the intrinsic death pathway (Rudner et al., 
2001). Prolonged activation of p53 due to massive DNA damage results in activation of pro-
apoptotic apoptosis regulator Bcl-2 (BCL-2) family members (e.g. apoptosis regulator BAX 
(BAX), Bcl-2-binding component 3 (PUMA), phorbol-12-myristate-13-acetate-induced 
protein 1 (NOXA)), and subsequent mitochondrial outer membrane permeabilization 
(MOMP) together with release of mitochondrial cytochrome c into the cytosol activate the 
caspase cascade. However, IR can also stimulate the upregulation of death receptor family 
INTRODUCTION 
8 
members that are required for the extrinsic apoptosis pathway. Although p53 is a central 
player in apoptosis induction, malignant cells with inactivating mutations in p53 can undergo 
IR-induced apoptosis via other mechanisms (e.g. p63/p73-dependent expression of pro-
apoptotic proteins) (Lauber et al., 2012).  
Apoptosis is less common in cells of epithelial origin (i.e. in most solid tumors). These 
cells display different forms of cell death upon irradiation (Deloch et al., 2016; Eriksson and 
Stigbrand, 2010). Limitations and deficiencies in apoptosis regulators can stimulate 
programmed necroptosis, which comprises hyperactivation of poly(ADP-ribose)polymerase 
(PARP), activation of receptor-interacting serine/threonine-protein (RIP) kinase, and 
depletion of intracellular adenosine triphosphate (ATP) levels. Characteristics of necroptosis 
are reactive oxygen species production, lipid peroxidation, organelle swelling, and 
disintegration of the cell membrane (Pasparakis and Vandenabeele, 2015; Vandenabeele et 
al., 2010). In case of very high irradiation doses, uncontrolled rupture of the plasma 
membrane and massive release of intracellular contents – termed primary necrosis – can 
occur (Lauber et al., 2012). Functionality of cell cycle checkpoints allows cells to leave the 
Figure 2 Ionizing radiation induces different forms of cell deaths and cellular 
senescence.  
IR causes DNA damage. When the DNA damage cannot be repaired via DDR, 
cancer cells undergo different forms of cell death or permanent cell arrest termed 
cellular senescence. Crucial determinants in this regard are the cellular origin, the 
genetic background, and the functionality of cell cycle checkpoints. MOMP, 
mitochondrial outer membrane permeabilization; PARP, poly(ADP-
ribose)polymerase; RIP kinase, receptor-interacting serine/threonine-protein kinase. 
Figure taken from (Lauber et al., 2012). 
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cell cycle irreversibly upon IR. They do not further proliferate but stay metabolically active. 
This permanent cell cycle arrest is termed cellular senescence and exhibits features of 
flattened and enlarged morphology, upregulation of cyclin-dependent kinase inhibitors (e.g. 
p16, p21, p27,), senescence-associated β-galactosidase activation, and involvement of p53 
(Nardella et al., 2011; Roos et al., 2016). Defects in cell cycle checkpoints force cells to 
undergo aberrant mitosis upon IR resulting in mitotic catastrophe as characterized by 
formation of giant cells with multiple nuclei and centrosome hyperamplification. Eventually, 
these cells can undergo cellular senescence, delayed apoptosis and/or necro(pto)sis, 
respectively (Eriksson and Stigbrand, 2010; Lauber et al., 2012). 
1.3.1.3 Immunological Potential of Irradiation-induced Cell Death Modalities 
Not only the induction of cancer cell death and the abrogation of clonogenic survival, but 
also the immunological potential of the different cell death modalities appears to be 
important for the treatment outcome of RT. Enhancing dying cancer cell immunogenicity by 
RT may favor the induction of anti-tumor immune mechanisms that can contribute to local 
as well as systemic tumor control. Along these lines, regression of distant, out-of-field 
metastases upon local RT (so-called abscopal effects) has been occasionally reported in the 
clinic (Demaria et al., 2004; Formenti and Demaria, 2009; Mole, 1953; Postow et al., 2012).  
Apoptotic tumor cells with intact plasma membrane are removed by antigen-presenting 
cells (APCs), including macrophages and DCs, in an immunologically silent or tolerogenic 
manner (Poon et al., 2014). Under certain conditions, this can even promote tumor 
progression (Ford et al., 2015; Huang et al., 2011). In contrast, necrotic forms of cell death 
are rather immunogenic and can trigger pro-inflammatory immune responses. Due to the 
loss of plasma membrane integrity, intracellular contents comprising tumor-antigens and 
damage-associated molecular patterns (DAMPs) are released and/or exposed from necrotic 
cells (Derer et al., 2015; Lauber et al., 2012). DAMPs include heat shock proteins (HSPs), 
high mobility group protein B1 (HMGB1), nucleotides, S100 proteins, and others (Garg et 
al., 2015; Kroemer et al., 2013; Krysko et al., 2012). They can instigate the recruitment of 
monocytes and DCs, the uptake of tumor antigens by DCs, their maturation, lymph node 
homing, and activation of naïve CD4+ and CD8+ T cells via (cross-) presentation of tumor-
antigens by DCs (Kroemer et al., 2013; Lauber et al., 2015). The resulting CD8+ T cell 
responses can contribute to the eradication of tumor cells – within the irradiation field, but 
in principle also systemically (Deloch et al., 2016; Formenti and Demaria, 2009). For 
senescent cells, only limited data regarding their immunogenic potential are available. They 
are known to produce various cytokines and chemokines (collectively termed 'senescence-
associated secretory phenotype') that has been reported contradictorily to initiate tumor 
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regression as well as tumor progression (Coppe et al., 2010; Perez-Mancera et al., 2014; 
Ruhland et al., 2016). 
For ablative RT regimes with high single doses, accumulating evidence suggests that 
several steps within the cancer-immunity cycle can be enforced (Figure 3) (Deloch et al., 
2016; Gaipl et al., 2014; Lauber et al., 2015). As such, the release of DAMPs derived from 
irradiated, necrotic cancer cells has been reported to recruit monocytes, which can function 
as precursor cells of APCs (Hennel et al., 2014). In vivo evidence has been provided for the 
intratumoral accumulation of APCs, originating from peripheral blood monocytes, upon 
ablative irradiation (Burnette et al., 2011). These intratumoral APCs can produce type I 
interferons (IFNs), thus supporting APC maturation, lymph node homing, and DC-mediated 
cross-priming of CD8+ T cells in the tumor draining lymph nodes (Burnette et al., 2011; 
Lugade et al., 2005). In turn, type II IFN-producing CD8+ T cells have been described to kill 
tumor cells via their cytolytic capacity (Gerber et al., 2013; Gupta et al., 2012). Finally, IR-
mediated upregulation of stress-induced ligands, adhesion molecules, death receptors, and 
major histocompatibility complex (MHC) class I molecules can enhance tumor 
immunogenicity, thereby increasing anti-tumor CD8+ T cell responses. For non-ablative RT 
Figure 3 Ablative radiotherapy and the cancer immunity cycle. 
Ablative RT with doses of more than 10 Gy can enforce various steps involved in 
the induction of anti-tumor immune responses finally resulting in tumor-specific 
killing by CD8+ T cells. DAMP, damage-associated molecular pattern. Figure taken 
from (Lauber et al., 2015). 
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regimes, including conventionally fractionated and hypofractionated RT, the involvement of 
effective anti-tumor immune responses is only poorly understood and currently under 
discussion. In these cases, combination with immunotherapeutic approaches appears 
promising in order to overcome the immunosuppressive tumor microenvironment and 
stimulate systemic anti-tumor immune mechanisms (Deloch et al., 2016; Frey et al., 2014; 
Lauber et al., 2015 ). 
1.3.2 Limitations of Radiotherapy 
Despite its essential role in cancer treatment, RT still faces several limitations regarding 
side effects and therapeutic failure. Side effects are caused by normal tissue damage, 
inflammation, and fibrosis. Their occurrence depends on various factors, including the RT 
scheme and total dose applied, the location of the tumor, radiosensitivity of the surrounding 
normal tissue, and patient-related, individual factors (Begg et al., 2011; Orth et al., 2014). 
Therapeutic failure, in contrast, can derive from intrinsic tumor cell radioresistance, 
increased repopulation, poor cell cycle redistribution of surviving tumor cells, and impaired 
reoxygenation between RT fractions (Baumann et al., 2016). Of special interest is intrinsic 
radioresistance that can be caused by the upregulation of various DDR mediators (Begg et 
al., 2011). In addition, the tumor microenvironment can contribute to impaired responses 
towards IR caused by hypoxia, fibrosis, and immunosuppressive effects (Barker et al., 2015).  
Consequently, a major focus of modern radiation oncology is to improve the therapeutic 
outcome by preferential sensitization of the tumor to IR and concurrent avoidance of side 
effects. In this regard, combined modality approaches of RT with molecularly targeted 
agents that interfere with essential drivers of malignancy, including regulators of the DDR, 
the EGFR pathway, angiogenesis, and other pathways, appear particularly promising (Begg 
et al., 2011; Maier et al., 2015; Morris and Harari, 2014). 
1.4 Molecularly Targeted Therapy 
Conventional chemotherapy is a systemic and cytotoxic anti-cancer treatment damaging 
all rapidly proliferating cells in the body. Over the last decades, cancer research focused on 
more selective and personalized approaches, such as molecularly targeted therapies. These 
molecularly designed agents address only a limited set of proteins – sometimes only one 
individual protein – which are essential for maintaining the malignant phenotype. Therefore, 
molecularly targeted therapies are assumed to have less frequent and less severe side effects 
as well as a higher efficacy than chemotherapeutics. These small molecule inhibitors or 
monoclonal antibodies specifically target individual signaling cascades, such as the EGFR 
pathway, the VEGFR pathway, DDR regulators, and others. 
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Several molecularly targeted therapies have already been integrated in current multimodal 
treatment approaches of certain cancers. The tyrosine kinase inhibitor imatinib initially 
received approval for Philadelphia chromosome-positive chronic myeloid leukemia 
inhibiting the BCR-ABL1 fusion protein (Druker, 2008). With identification of other 
imatinib targets, such as mast/stem cell growth factor receptor Kit (SCFR) and PDGFR, 
approval was extended to GISTs harboring mutations in KIT and to DFSP with a gene fusion 
leading to overexpression of PDGFR (Demicco et al., 2012; Taylor et al., 2011). Meanwhile, 
treatment of metastatic CRC comprises the application of the molecularly designed agents 
bevacizumab targeting vascular endothelial growth factor A (VEGF-A), as well as 
cetuximab and panitumumab both interfering with EGFR signaling (Ahn et al., 2016; 
Cunningham et al., 2010). Interestingly, the observation that EGFR overexpression 
correlates with radioresistance was the initial step for the approval of cetuximab in 
combination with RT for squamous cell carcinoma of the head and neck. Several preclinical 
studies provide evidence for molecularly targeted sensitization to RT by different substances 
(Giaccia, 2014; Morris and Harari, 2014). Nevertheless, the efficacy of these approaches 
will clearly depend on appropriate patient stratification with versatile predictive biomarkers 
and the absence and/or the control of severe toxicities.  
1.5 Heat Shock Protein 90 as Promising Target for Anti-Cancer 
Therapy 
Since multiple and – to a certain degree – redundant signaling pathways contribute to the 
maintenance of malignant phenotype, pharmacological interference with one single protein 
and/or pathway might be compensated by others and can lead to inefficient response or 
therapy resistance, respectively. Therefore, it appears promising to target multiple oncogenic 
signaling pathways simultaneously. A protein involved in diverse signaling cascades 
orchestrating the hallmarks of cancer is the chaperone HSP90.  
1.5.1 The Molecular Chaperone Heat Shock Protein 90 
HSP90 is a member of the heat shock protein family with a molecular weight (MW) of 
90 kDa. The ATP-dependent chaperone prevents protein aggregation by mediating 
maturation, activation, and stabilization of its substrates, referred to as client proteins (Saibil, 
2013; Taipale et al., 2010). These client proteins are involved in several signaling pathways 
and control various cellular features, including cellular growth, proliferation, differentiation, 
and death. HSP90 and other HSPs are upregulated and activated under different stress 
conditions, such as heat, irradiation, hypoxia, and acidosis (Whitesell and Lindquist, 2005). 
Evolutionarily, HSP90 is highly conserved and can be found in all organisms apart from 
archaea. In humans, the HSP90 family comprises different gene products. HSP90-α1 and 
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HSP90-α2 are encoded by HSP90AA1 and HSP90AA2, and HSP90-β by HSP90AB1. Under 
non-stress conditions, gene products of these paralogs account for 1%-2% of the total protein 
content in the cytoplasm, but they can also be found in the nucleus. Further HSP90 family 
members are localized in other cellular compartments: 94 kDa glycose-related protein 94 
(GRP94) in the endoplasmic reticulum and tumor necrosis factor type 1 receptor-associated 
protein (TRAP1) in the mitochondria (Chen et al., 2006; Johnson, 2012; Taipale et al., 2010).  
HSP90 clients are folded via the HSP90 chaperone cycle with the help of several co-
chaperones, such as stress-induced-phosphoprotein 1 (STI1), HSP70, HSP40, and activator 
of 90 kDa heat shock protein ATPase homolog 1 (AHA1) (Figure 4A). The flexible HSP90 
dimer consists of three different domains exerting specific functions: the N-terminal domain 
binds ATP, the middle domain interacts with the client protein, and the C-terminal domain 
is responsible for dimerization during the chaperone cycle. In the course of this highly 
dynamic process, HSP90 switches between an open conformation via an intermediate state 
to the closed and twisted conformation. Eventually, under hydrolysis of ATP, the client 
protein is correctly folded and dissociates from the chaperone complex (Trepel et al., 2010). 
Meanwhile, several asymmetric processes, such as interactions with co-chaperones and 
posttranslational modifications (e.g. phosphorylation, acetylation), are known to fine-tune 
the chaperone cycle (Mayer and Le Breton 2015). All small molecule inhibitors of HSP90 
that have been clinically evaluated so far bind competitively to the unique N-terminal ATP-
Figure 4 Simplified scheme of the dynamic HSP90 chaperone cycle.  
(A) HSP90 and various co-chaperones (not shown here) mediate the folding of client 
proteins under several conformational changes and ATP hydrolysis. (B) The vast 
majority of HSP90 inhibitors competitively interfere with N-terminal ATP binding 
and prevent the chaperoning activity of HSP90. This hampers the maturation of the 
client protein that will be released and subjected to proteasomal degradation. ATP, 
adenosine triphosphate; ADP, adenosine diphosphate; HSP90, heat shock protein 
90; P, phosphate. Figure taken from (Lauber et al., 2015). 
INTRODUCTION 
14 
binding domain with a high degree of affinity. This leads to the sequence of events: 
prevention of ATP binding and hydrolysis, release of misfolded client proteins, and finally 
their proteasomal degradation (Figure 4B). Depletion of several hundred client proteins, 
including protein kinases and transcription factors (for an up-to-date list see 
http://www.picard.ch/downloads/HSP90interactors.pdf), can interfere with basically all 
hallmarks of cancer (Lauber et al., 2015; Neckers and Workman, 2012). 
1.5.2 Heat Shock Protein 90 Inhibition Interferes with Multiple 
Hallmarks of Cancer 
Cancer cells exhibit a stronger dependency on HSP90 folding assistance than normal 
cells. Overexpressed HSP90 in cancer cells compensates for stress associated with the 
malignant phenotype, such as aneuploidy, proteotoxic stress, nutrient starvation, and 
hypoxia. In addition, HSP90 supports the stability and function of mutated, translocated, 
and/or overexpressed oncoproteins, which are particularly labile. Thus, HSP90 has emerged 
as an interesting target for anti-cancer therapies. Pharmacological inhibition of HSP90 
represents a multi-target approach, since many of the hundreds of HSP90 client proteins 
contribute to the establishment and the maintenance of the hallmarks of cancer (Figure 5) 
(Calderwood and Gong, 2016; Neckers and Workman, 2012). ‘Sustaining proliferative 
signaling’ in cancer cells is facilitated by ligand-mediated oncogenic growth factor receptor 
signaling, mainly due to activating mutations or overexpression of cell surface tyrosine 
kinases. These tyrosine kinases, including receptor tyrosine-protein kinase erbB-2 (ERBB2) 
or EGFR, as well as their downstream signaling mediators in the PI3K/protein kinase B 
(AKT) and the mitogen-activated (MAP) kinases pathway are HSP90 client proteins and, 
thus, sensitive to its inhibition (Lauber et al., 2015). For ‘evading growth suppression’, the 
chaperone is involved in the stabilization of clients regulating the cell cycle, the cyclin-
dependent kinases (CDKs), and their ligands. Hence, cell cycle progression can be disrupted 
by HSP90 inhibition (Xu and Neckers, 2007). ‘Resisting cell death’ is sustained by HSP90 
through stabilization of anti-apoptotic AKT signaling associated with inactivation of pro-
apoptotic BCL-2 family member Bcl2-associated agonist of cell death (BAD), prevention of 
cytochrome C release via overexpression of anti-apoptotic BCL-2, and activation of pro-
survival factors (Lauber et al., 2015). Malignant cells have the feature to overcome the life-
span limiting shortening of telomeres by overexpression of the enzyme telomerase. HSP90 
is required for the enzymatic activity of the human telomerase reverse transcriptase 
(hTERT). Correspondingly, inhibition of HSP90 prevents elongation of telomeres and 
therefore interferes with the hallmark ‘enabling replicative immortality’. The chaperone also 
contributes to ‘inducing angiogenesis’. HSP90 stabilizes the oxygen level-sensing 
transcription factor hypoxia-inducible factor 1-alpha (HIF-1α) that controls the transcription 
INTRODUCTION 
15 
of VEGF. Binding of VEGF to its receptor VEGFR that is also a known HSP90 client protein 
induces – amongst many other aspects of angiogenesis – endothelial cell proliferation (Xu 
and Neckers, 2007). Furthermore, HSP90 inhibition interferes with ‘activating invasion and 
metastasis’, since several of its clients are involved in this hallmark. In this context focal 
adhesion kinase should be mentioned exemplarily as well as ephrin receptors, the tyrosine-
protein kinase Met (MET), matrix-metalloproteases, and mediators of epithelial-
mesenchymal transition. A direct effect on tumor cell migration has been reported for 
ectopic, membrane-bound HSP90 that is only expressed in malignant cells. Several HSP90 
clients (e.g. RAF proto-oncogene serine/threonine-protein kinase, AKT, Myc proto-
oncogene protein (MYC)) support ‘deregulating cellular energetics’ that e.g. includes 
anaerobic glycolysis for generation of glycolytic intermediates needed for assembling new 
Figure 5 Overview of HSP90 inhibitors interfering with multiple hallmarks of 
cancer simultaneously.  
Exemplary selected HSP90 client proteins are displayed that contribute to the 
establishment and the maintenance of different hallmarks of cancers, thereby 
promoting the transition of a normal cell into a malignant cell. AKT, protein kinase 
B; CDK, cyclin-dependent kinase; EGF-R, epidermal growth factor receptor; EMT, 
epithelial-mesenchymal transition; EPHA2, ephrin type-A receptor 2; FLIP, FLICE-
inhibitory protein; HER2/NEU, human epidermal growth factor receptor 2; HIF-1α, 
hypoxia-inducible factor 1-alpha; hTERT, human telomerase reverse transcriptase; 
IAP, inhibitor of apoptosis protein; MET, tyrosine-protein kinase Met; MYC, Myc 
proto-oncogene protein; RAF, RAF proto-oncogene serine/threonine-protein kinase; 
VEGF-R, vascular endothelial growth factor receptor. Figure taken from (Lauber et 
al., 2015).  
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cells. Nevertheless, the influence of HSP90 inhibition on malignant cell metabolism is only 
poorly understood (Lauber et al., 2015).  
Finally, HSP90 inhibition also counteracts ‘avoiding immune destruction’ in various 
ways. First, stress-inducible proteins, such as HSP70 and the natural killer group 2D 
(NKG2D) ligands MHC class I polypeptide-related sequence A and B (MIC-A and -B), are 
upregulated on the tumor cell surface upon HSP90 inhibition. These proteins stimulate 
activation, migration, and cytolytic activity of natural killer cells (NKCs) (Lauber et al., 
2015). Second, HSP90 inhibition can restore the recognition of tumor cells by overcoming 
the loss of tumor antigen presentation. HSP90 inhibitors promote the accelerated degradation 
of highly expressed oncogenic HSP90 clients (e.g. HER2/NEU, ephrin type-A receptor 2 
(EPHA2)) and the presentation of peptides derived thereof on MHC class I molecules on the 
tumor cell surface. Thus, tumor cells are sensitized towards CD8+ T cell-mediated lysis 
(Castilleja et al., 2001; Kawabe et al., 2009). Additionally, increased expression of tumor-
specific differentiation antigens and MHC class I molecules that are no HSP90 client 
proteins contribute to enhanced tumor cell recognition by CD8+ T cells (Haggerty et al., 
2014). Third, HSP90 inhibition renders the tumor microenvironment favorable to the 
infiltration of CD4+ and CD8+ T cells and reduces the intratumoral levels of 
immunosuppressive myeloid-derived suppressor cells (MDSCs) and regulatory T cells 
(Tregs) (Rao et al., 2012). In contrast, even low concentrations of HSP90 inhibitors are 
considered to suppress DC and T cell functions (Bae et al., 2007; Schnaider et al., 1998). 
Nevertheless, a dominance of immunostimulatory effects is assumable, since HSP90 
inhibitors specifically accumulate in cancer cells (see 1.5.3). Further studies will elucidate 
whether HSP90 inhibition might also interfere with the two enabling characteristics ‘genome 
instability and mutation’ and ‘tumor-promoting inflammation’. 
1.5.3 Heat Shock Protein 90 Inhibitors Exhibit a High Degree of Cancer  
Cell Selectivity 
The strong dependency of cancer cells on HSP90 chaperoning assistance and the 
association of elevated HSP90 expression in cancer with poor overall survival make HSP90 
an attractive target for anti-cancer therapy (Cheng et al., 2012; Neckers and Workman, 2012; 
Wang et al., 2013; Whitesell and Lindquist, 2005). Nevertheless, a prerequisite for clinical 
translation of HSP90 inhibitors is a relevant degree of selectivity for HSP90 in cancer cells 
as compared to HSP90 in normal cells particularly when some normal tissues express HSP90 
at higher levels (brain, spleen, bladder) than e.g. breast cancer cells (Barrott and Haystead, 
2013). First of all, the majority of HSP90 inhibitors bind to the N-terminal ATP-binding 
domain that is defined as the Bergerat fold. This Bergerat fold is structurally unique to the 
small GHKL (Gyrase, HSP90, histidine kinase, MutL) subgroup within the ATPase 
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superfamily, thereby exhibiting high specificity for HSP90 and not for other ATPases or 
kinases (Neckers and Workman, 2012; Pearl and Prodromou, 2006). Second, HSP90 
inhibitors were indeed found to accumulate specifically in tumors and are rapidly cleared 
from circulation (Porter et al., 2010). Although the molecular basis of this observation 
remains to be fully elucidated, some suggestions were already made ranging from existence 
of high multi-chaperone complexes in malignant cells with high affinity for HSP90 
inhibitors, preferred binding of small molecule drugs to HSP90 found in complex with 
oncoproteins, to posttranslational modifications of the chaperone influencing the affinity for 
HSP90 inhibitors (Kamal et al., 2003; Mollapour et al., 2014; Moulick et al., 2011). In 
addition, HSP90 inhibitor binding to ectopic, membrane-localized HSP90 that is only 
expressed in malignant cells might contribute to accumulation of small molecule HSP90 
inhibitors in tumor cells via internalization of the formed complexes (Barrott et al., 2013). 
All this contributes to preferential anti-cancer activity of HSP90 inhibitors at doses that are 
in principal tolerated by the normal tissue.  
1.5.4 Clinical Development of the Heat Shock Protein 90 Inhibitors  
The first HSP90 inhibitors were the natural compounds geldanamycin (a benzoquinone 
ansamycin antibiotic) and radicicol (an antifungal, antibiotic macrocyclic resorcinol). This 
first generation of HSP90 activity blocking compounds exhibited unfavorable 
pharmacological properties, including toxicities, poor solubility, and insufficient 
bioavailability, thus prohibiting their translation into the clinic (Table 1). The second 
generation of HSP90 inhibitors, which are derivatives of the natural compounds, displayed 
improved properties (Alarcon et al., 2012; Garcia-Carbonero et al., 2013). However, 
geldanamycin and its derivatives 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) 
and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) still exhibited 
hepatotoxicity that derives from their quinone-structure. In the hepatic metabolism of these 
drugs, NADPH-cytochrome P450 reductase and NADH cytochrome b5 reductase generate 
unstable semi-quinones and toxic xenobiotic epoxides (Egorin et al., 1998; Guo et al., 2008). 
Reaction of the drugs with thiol groups of hepatic glutathione forms further toxic conjugates 
(Cysyk et al., 2006). This led to the development of a third generation of fully synthetic 
HSP90 inhibitors that are structurally unrelated to the precursor drugs, including purine 
scaffold compounds, resorcinylic pyrazole amides, and isoxazole amides. These compounds 
exhibit improved potency, bioavailability, and application (Lauber et al., 2015). Currently, 
17 different HSP90 inhibitors are undergoing clinical evaluation, but so far none of them 
received approval for clinical use (Neckers and Trepel, 2014). Among the most advanced 
agents is the resorcinol-based STA-9090 (ganetespib, Synta Pharmaceuticals) that is 
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currently undergoing phase III evaluation in combination with docetaxel in patients with 
advanced non-small-cell lung cancer (NCT01798485).  
In comparison to geldanamycin and its derivatives, the natural, none-quinone structured 
radicicol avoids hepatotoxicity, but has weak bioactivity in vivo presumably due to lack of 
stability (Agatsuma et al., 2002). Hence, diverse efforts were undertaken in order to develop 
derivatives of radicicol with improved stability and pharmacokinetics. Prof. Nicolas 
Winssinger and his lab generated a library of pochoximes, which are based on the radicicol 
pharmacophore, identifying novel, highly potent HSP90 inhibitors with improved efficacy 
at nanomolar concentrations. Pochoxime-derived HSP90 inhibitors have been reported to 
induce apoptosis and reduce tumor growth in breast cancer xenografts and in a genetically 
engineered mouse model of glioblastoma multiforme (Barluenga et al., 2009; Barluenga et 
al., 2008; Wang et al., 2009; Zhu et al., 2010). For the present study, epi-pochoxime F 
(NW457) was used. It is a highly potent HSP90 inhibitor of the pochoxime series (Nexgenix 
Pharmaceuticals) with an HSP90 binding KD (dissociation constant) of approximately 14 
nM (Karthikeyan et al., 2012).  
In general, the best therapeutic success of HSP90 inhibitors is expected in tumors that 
rely heavily on driver oncogenes requiring HSP90 assistance (e.g. ALK tyrosine kinase 
receptor (ALK), HER2/NEU, EGFR) and tumors in which HSP90 buffers high levels of 
proteotoxic stress (e.g. multiple myeloma) (Neckers and Workman, 2012). So far, anti-tumor 
Table 1 Overview of HSP90 inhibitors under clinical evaluation. 
Table taken from (Lauber et al., 2015). 
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efficacy of HSP90 inhibition was moderate when applied as monotherapy. Interestingly, 
accumulating evidence suggests a synergistic mode of action for HSP90 inhibitors in 
combination with other anti-cancer therapies, including RT (Butler et al., 2015; Whitesell 
and Lin, 2012).  
1.6 Radiotherapy plus Heat Shock Protein 90 Inhibition  
HSP90 inhibition provides a multi-target approach of cancer cell-selective 
radiosensitization by overcoming intrinsic radioresistance – a complex phenomenon that is 
coordinated by several regulators involved in pleotropic signaling pathways (e.g. ATM, 
CHK1, focal adhesion kinase 1 (FAK), EGFR). Some of these molecular drivers are known 
HSP90 client proteins. Consequently, pharmacological blockade of HSP90 leads to 
simultaneous depletion of proteins that are essential for the response to IR, particularly DDR 
regulators and protein kinases. Degradation of DDR regulators results in hampered repair of 
irradiation-induced DNA damage, which can be measured by delayed or impaired clearance 
of irradiation-induced γH2AX foci (Camphausen and Tofilon, 2007; Lauber et al., 2015). 
On the molecular level, HSP90 inhibition compromises the two major repair mechanisms 
for irradiation-induced DSBs, NHEJ and HR. NHEJ is affected by impaired activation of the 
catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), and HR is hampered by 
proteasomal degradation of the HSP90 client proteins BRCA1, BRCA2, and DNA repair 
protein RAD51 homolog 1 (RAD51). In addition, the function of central upstream regulators 
of the DDR is disrupted. Upon HSP90 inhibition, the HSP90 client protein CHK1 lacks 
folding assistance, and activation of ATM is impaired due to reduced MRN complex-
dependent phosphorylation, since MRN's ability to form IR-mediated nuclear foci is 
compromised (Pennisi et al., 2015). Furthermore, ATR has been reported as a bona fide 
HSP90 client protein, and therefore HSP90 inhibition reduces ATR levels (Ha et al., 2011). 
Preclinical studies in different cancer entities revealed an association of HSP90 inhibitor-
mediated radiosensitization with impairment of the DDR, disruption of cell cycle arrest, 
reduction in cellular proliferation, increase in cell death, abrogation of clonogenic survival, 
and attenuation of tumor growth (Camphausen and Tofilon, 2007; Lauber et al., 2015). 
However, although the radiosensitizing potential of HSP90 inhibitors has been known for 
more than a decade, it took several years for the first HSP90 inhibitor (the resorcinol-based 
AT13387) to enter clinical testing in combination with RT and cisplatin in patients with 
locoregionally advanced squamous cell carcinoma of the head and neck (NCT02381535). 
Interestingly, combination of RT with HSP90 inhibition appears to have even more 
advantages. HSP90 inhibitors specifically radiosensitize cancer cells, thereby improving the 
therapeutic width (Kabakov et al., 2010). Furthermore, the underlying synergistic mode of 
action between RT and HSP90 inhibition seems to provide a better therapeutic outcome with 
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the same irradiation dose, or a reduced risk of irradiation-induced side effects by allowing 
the use of lower irradiation doses, respectively. It might also be speculated that RT plus 
HSP90 inhibition has the potential to enhance tumor cell immunogenicity, since some RT 
regimes and HSP90 inhibition alone display immunostimulatory potential. However, the 
impact of the immune system on the efficacy of HSP90-mediated radiosensitization so far is 
poorly understood (Lauber et al., 2015).  
Hence, HSP90 inhibition appears to be a promising partner for RT with regard to 
reduction of RT-related side effects by overcoming intrinsic radioresistance, improving the 
therapeutic width, and possibly enhancing tumor cell immunogenicity. 
  
OBJECTIVE 
21 
2 Objective 
Intrinsic radioresistance is a major cause of radiotherapeutic failure. To overcome this 
limitation, the aim of the present study was the identification of biomarkers associated with 
intrinsic radioresistance and their potential pharmacological exploitation in order to improve 
the therapeutic width. Based on a set of newly identified biomarkers, the efficacy of HSP90 
inhibitor-mediated sensitization of radioresistant STSs towards IR was analyzed in vitro. 
Moreover, in models of CRC, HSP90 inhibition was examined with special regard to its 
radiosensitizing potential, its tolerability, and its capacity to enhance tumor cell 
immunogenicity in combination with RT in vitro and in vivo. 
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5 Summary and Discussion of Publications 
5.1 HSP90 Inhibition as a Means of Radiosensitizing Resistant, 
Aggressive Soft Tissue Sarcomas 
RT is an integral part of the multimodal treatment of STSs (Demetri et al., 2010; Group, 
2014; von Mehren et al., 2014). Nonetheless, radiotherapeutic failure commonly occurs as a 
result of intrinsic tumor radioresistance (Barker et al., 2015; Begg et al., 2011). Since the 
sensitivity towards irradiation differs considerably among STSs (Rhomberg, 2006), 
identification of appropriate biomarkers of radioresistance is of high interest – not only in terms 
of risk assessment and individualization of treatment plans, but also for improvement of RT by 
combination with radiosensitizing agents that can target those biomarkers (Wong et al., 2014).  
The motivation of this study was to identify biomarkers of intrinsic radioresistance that can 
be used for STS patient stratification and to provide new potential approaches for molecularly 
targeted radiosensitization. To the best of our knowledge, this is the first systematic study on 
intrinsic radioresistance in this cancer entity. We analyzed several human STS cell lines 
regarding their intrinsic radioresistance. Colony formation assays revealed strong differences 
in clonogenic survival upon IR. The survival data were subjected to linear-quadratic fitting to 
obtain α/β values as well as to principal component analysis (PCA) to extract scores of 
radioresistance, both parameters describing radioresistance in a quantitative manner (Franken 
et al., 2013; Unkel et al., 2016). These analyses separated two clusters of STS cell lines, one 
with lower and one with higher resistance towards irradiation. Since improved and/or 
accelerated DNA damage repair is commonly considered to contribute to intrinsic 
radioresistance (Begg et al., 2011; Bouwman and Jonkers, 2012), we performed transcriptomic 
profiling by quantitative real-time RT-PCR (qRT-PCR) analyses of DDR regulators in order to 
find of candidates whose expression levels correlate with radioresistance. The three DDR 
regulators whose mRNA expression levels revealed the strongest positive correlations with the 
PCA-derived radioresistance scores were ATM, ATR, and Nijmegen breakage syndrome 
(NBS1, a member of the MRN complex). The MRN complex is crucial for the recognition of 
irradiation-induced DSBs and subsequent activation of the protein kinase ATM as well as for 
the regulation of ATR-mediated processes within the DDR, thereby activating downstream 
DNA repair mediators (Ciccia and Elledge, 2010). Intriguingly, ATM, ATR, and NBS1 have 
been reported to be dependent on the folding assistance of the molecular chaperone HSP90, 
either via direct protein stabilization (in the case of ATR and the MRN complex) or via 
mechanisms involved in protein activation (in the case of ATM) (Dote et al., 2006; Ha et al., 
2011; Pennisi et al., 2015). In line with this, the expression levels of the HSP90 isoform 
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HSP90AB1 also strongly correlated with the scores of radioresistance. Query of the STS cohort 
of the Cancer Genome Atlas (TCGA) database revealed that upregulated expression levels of 
HSP90 (particularly isoform HSP90AB1), ATM, ATR, and/or NBS1 are associated with 
impaired clinical outcome. This underlines the clinical relevance of these candidate biomarkers 
as well as the potential of their molecular targeting in the context of multimodal RT of STSs. 
The results described above encouraged us to examine whether HSP90 inhibition can 
sensitize STS cell lines to IR, since regulators of the DDR have been reported to be 
preferentially sensitive to HSP90 inhibition (Sharma et al., 2012). Hence, HSP90 inhibition has 
emerged as a promising means of radiosensitization (Camphausen and Tofilon, 2007; Kabakov 
et al., 2010). For our study, we used the novel HSP90-inhibiting pochoxime-derivative NW457 
(Barluenga et al., 2009; Barluenga et al., 2008; Karthikeyan et al., 2012; Wang et al., 2009). 
Pretreatment with low nanomolar concentrations of NW457 for 24 h was sufficient to sensitize 
radioresistant STS cell lines towards irradiation as revealed by a significant reduction in 
clonogenic survival. Mechanistically, NW457-mediated radiosensitization was accompanied 
by a delayed clearance of γH2AX DNA damage repair foci and by a time-dependent 
downregulation of the crucial DNA damage repair mediators ATM, ATR, CHK1, and RAD51 
on the protein level. Abrogation of clonogenic survival has been reported to be mediated by cell 
cycle arrest and induction of cell death upon HSP90 inhibitor-mediated radiosensitization 
(Chettiar et al., 2016; Kinzel et al., 2016; Spiegelberg et al., 2015). Indeed, pretreatment with 
NW457 led to an enhancement of basal and irradiation-induced cellular senescence in 
radioresistant cell lines. This suggests an involvement of cellular senescence in this context, 
whereas apoptosis and necrosis were only observed upon treatment with higher concentrations 
of NW457.  
So far, different efforts have been undertaken in order to improve RT of STSs. Very 
promising strategies appear to be the use of hyperthermia integrated into multimodal therapy 
concepts and irradiation with carbon ions instead of photons (DeLaney et al., 2005; Jingu et al., 
2012; Lindner and Issels, 2011). The efficacy of radiochemotherapy for STSs is controversially 
discussed, and the risk of subsequently occurring side effects should not be neglected (Curtis et 
al., 2011; Look Hong et al., 2013). With increasing knowledge of the mechanistic 
characteristics of STS radioresistance, molecularly targeted agents have been developed. These 
molecular drugs, which specifically target protein kinases (e.g. VEGFR, mTOR) or HDACs, 
respectively, have shown potent radiosensitization in preclinical studies, and thus are currently 
being evaluated in clinical trials (Blattmann et al., 2010; Canter et al., 2014; Murphy et al., 
2009; Rao et al., 2014; Wong et al., 2014). As shown here, HSP90 inhibition is a specifically 
attractive approach for targeted radiosensitization. HSP90 inhibitors have the potential to target 
multiple HSP90 client proteins that contribute to intrinsic radioresistance at once, and they can 
simultaneously interfere with the function of other client proteins that are involved in various 
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oncogenic signaling pathways, including growth factor receptors, downstream signaling 
mediators, and others (Camphausen and Tofilon, 2007; Kabakov et al., 2010; Lauber et al., 
2015). 
This first systemic study on intrinsic radioresistance in STSs describes HSP90 inhibition as 
a promising approach for targeted radiosensitization. Our in vitro studies identified ATM, ATR, 
NBS1, and HSP90 as potential biomarkers for intrinsic radioresistance due to strong positive 
correlations of their mRNA expression levels with intrinsic STS cell radioresistance. The 
clinical relevance of our findings is underlined by poor overall survival of patients with 
aggressive STSs displaying elevated expression levels of HSP90 itself and/or its client proteins 
ATM, ATR, and/or NBS1. Pharmacological targeting of HSP90 and its client proteins with the 
novel HSP90 inhibitor NW457 led to preferential radiosensitization of particularly resistant 
STS cell lines. Mechanistically, induction of cellular senescence but not apoptosis or necrosis 
appears to be involved. 
With respect to the TCGA data, a specific subgroup of STS patients with particularly high 
expression levels of the identified biomarkers might benefit most from HSP90 inhibitor-
mediated radiosensitization. So far, preclinical studies with HSP90 inhibition as monotherapy 
have reported its efficacy in different histological subtypes of STSs as measured by a reduction 
in cell proliferation, induction of apoptosis, and improvement of tumor control in xenograft 
models (Lesko et al., 2007; Smyth et al., 2012; Steinmann et al., 2015). A phase I study with 
HSP90 inhibitor single treatment has shown a stable disease in 60%-70% of STS patients and 
a good tolerability (Wagner et al., 2013). However, accumulating evidence suggests that HSP90 
inhibition is considerably more powerful when combined with other anti-cancer therapies, 
including RT, as compared to monotherapy concepts (Butler et al., 2015). This is in accordance 
with our results showing that HSP90 inhibition has much stronger effects in combination with 
RT than as mono-agent. In addition, it is feasible to assume that HSP90 inhibitors perform 
better in combination with RT than specific inhibitors of ATM, ATR, or the MRN complex (if 
available), respectively, since HSP90 inhibitors can target multiple client proteins involved in 
the DDR simultaneously. Nevertheless, further studies have to evaluate this assumption in 
greater depth. 
Besides enhancing irradiation-induced cell death and enforcing the reduction in clonogenic 
survival, HSP90 inhibition has the potential to favor anti-tumor immune mechanisms (Castilleja 
et al., 2001; Fionda et al., 2009; Haggerty et al., 2014; Kawabe et al., 2009). This is of special 
interest for the establishment of local and particularly systemic tumor control. Upon HSP90 
inhibition, the immunogenicity of cancer cells can be enhanced by increased production and 
release of DAMPs (Lauber et al., 2015). Furthermore, studies in an in vivo sarcoma model 
provided evidence for HSP90 inhibitor-mediated reprogramming of the tumor 
microenvironment. This comprised an increase in intratumoral CD8+ T cells and a decrease in 
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tumor infiltrating immunosuppressive cell subsets, such as MDSCs and Tregs (Rao et al., 2012). 
Since RT has been reported to stimulate upregulation of immune effectors markers and 
downregulation of immune suppressor markers in sarcoma samples (Sharma et al., 2013), 
additional HSP90 inhibition may even be able to boost these immunological effects. Further 
investigations are needed in order to dissect the immunostimulatory potential of RT plus HSP90 
inhibition in general and to elucidate the specific relevance of different modes of cell death in 
this scenario, particularly that of cellular senescence.  
In summary, our study identifies overexpression of HSP90 (particularly isoform HSP90AB1) 
and its client proteins ATM, ATR, and NBS1 as potential biomarkers of radioresistance in 
aggressive STSs. This special subgroup of STS patients may particularly benefit from 
molecularly targeted therapy with HSP90 inhibitors in combination with RT. 
My contribution to this study:  
As shared first author of this publication, I made major contributions to the initiation and 
design of this study. I planned, designed, and performed experiments. I analyzed and discussed 
experimental results leading to the next steps in the study. In addition, I discussed and 
commented on the manuscript. As part of this study, I methodologically supervised Heidi 
Kapfhammer´s medical doctoral thesis. 
In detail, I made the following experimental contributions: 
 Experiments on the induction of apoptosis and necrosis upon treatment with different 
concentrations of NW457 (Fig. 5A,B) 
 Colony formation assays for analyses of clonogenic survival of STS cell lines in 
response to irradiation and additional HSP90 inhibitor pretreatment (Fig. 4A) 
 qRT-PCR analyses for transcriptional profiling of DDR regulators (Fig. 2A) 
5.2 A Novel HSP90 Inhibitor with Reduced Hepatotoxicity 
Synergizes with Radiotherapy to Induce Apoptosis, Abrogate 
Clonogenic Survival, and Improve Tumor Control in Models 
of Colorectal Cancer 
For rectal cancer, RT is commonly applied in neoadjuvant or adjuvant settings within 
multimodal therapy concepts. In case of colon cancer, it is only occasionally used due to a high 
degree of colon mobility, considerable radiosensitivity of the surrounding normal tissue, and 
the corresponding difficulties in designing and delivering proper RT treatment plans 
(Glimelius, 2002; van de Velde et al., 2014; Willett et al., 1999). Therefore, it is of great interest 
to find substances that can sensitize CRC cells to IR and thereby can increase the therapeutic 
width. HSP90 inhibitors have emerged as attractive partners for RT, since HSP90 client 
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proteins, such as DDR regulators, play essential roles in the cellular response to IR and mediate 
intrinsic radioresistance (Begg et al., 2011; Maier et al., 2015; Sharma et al., 2012). Whereas 
preclinical studies have shown a strong synergizing potential of HSP90 inhibitors towards 
irradiation in several cancer entities, in vivo studies are rare and are mainly confined to 
xenograft models in immunocompromised mice (Kabakov et al., 2010). Moreover, clinical 
translation of first and second generation of HSP90 inhibitors has been hampered due to 
suboptimal pharmacological properties and severe hepatotoxicity (Garcia-Carbonero et al., 
2013).  
The study was designed to examine whether the novel pochoxime-based HSP90 inhibitor 
NW457, which was developed with the special focus on improved pharmacological properties 
and tolerability (Barluenga et al., 2009; Barluenga et al., 2008; Karthikeyan et al., 2012; Wang 
et al., 2009), has the potential to effectively sensitize CRC towards IR in vitro and in vivo. Our 
tolerability analyses provided encouraging results as they showed virtually no impairment in 
primary murine hepatocyte viability in vitro. Cell death assays disclosed that pretreatment with 
NW457 for 24 h synergistically sensitizes human HCT116 CRC cells to irradiation-induced 
apoptosis over a wide range of irradiation doses and inhibitor concentrations as determined by 
isobologram analysis and calculation of combination indices (Chou and Talalay, 1984; Niyazi 
and Belka, 2006). Apoptosis induction was accompanied by activation of caspases 9 and 3, 
cleavage of caspase substrates, chromatin condensation, and fragmentation of DNA, thus 
suggesting an involvement of the intrinsic apoptosis signaling pathway in this scenario. Later 
on, apoptotic cells underwent subsequent secondary necrosis as measured by time course flow 
cytometric analyses in the presence or absence of the poly-caspase inhibitor carbobenzoxy-
valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (zVAD-fmk). In contrast, addition of the 
RIP-1 kinase inhibitor necrostatin-1s excluded a relevant contribution of necroptosis in this 
context, which is in line with other studies reporting interference of HSP90 inhibition with 
necroptosis induction (Jacobsen et al., 2016; Zhao et al., 2016).  
For mechanistic studies on irradiation-induced intrinsic apoptosis with or without additional 
HSP90 inhibition, two subclones of HCT116 wildtype cells with genetic deficiencies in TP53 
or BAX were employed. Although intrinsic apoptosis is considered to be predominately 
regulated by the tumor suppressor p53 (Belka et al., 2004; Eriksson and Stigbrand, 2010), the 
TP53-/- subclone showed apoptosis levels comparable to those of the HCT116 wildtype cells 
upon NW457 treatment and irradiation. However, the number of synergistic combinations was 
reduced. A more detailed examination of pro- and anti-apoptotic proteins suggested a 
contribution of the pro-apoptotic cell cycle regulator p14ARF in p53-deficient cells. BAX-/- cells 
lacking the pro-apoptotic BCL-2 family member BAX displayed a strong reduction in apoptosis 
levels with almost no synergistic mode of action at all, thus indicating the dominance of BAX-
dependent apoptosis mechanisms upon NW457 treatment in combination with irradiation and 
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only a minor contribution of BAX-independent mechanisms. Transition into secondary necrosis 
was reduced in p53-deficient cells as compared to the wildtype controls, and in the BAX-
deficient cells secondary necrosis was hardly detectable, which is in accordance with the low 
levels of apoptosis. 
Long-term colony formation assays showed a significant reduction in clonogenic survival of 
HCT116 cells upon HSP90 inhibition in combination with irradiation, irrespective of the p53 
or BAX status. This was accompanied by the degradation of two essential upstream kinases of 
the DDR, ATM and CHK1, and a delay in DNA damage repair as indicated by impaired 
clearance of γH2AX foci.  
In vivo anti-tumor efficacy of NW457 treatment in combination with RT was analyzed in a 
syngeneic, heterotopic tumor model. Colorectal CT26 tumor-bearing Balb/c mice were 
subjected to repeated intraperitoneal administration of 100 mg/kg NW457 or the vehicle control 
and/or local irradiation with two fractions of 5 Gy. In comparison to the exponentially growing 
tumors in the vehicle control animals, NW457 delayed tumor expansion in the beginning, but 
exponential growth was rapidly restored. Irradiation alone revealed a stronger attenuation of 
tumor growth than NW457 treatment. However, the best tumor control was observed in mice 
that were subjected to the combined treatment, and Kaplan-Meier analyses disclosed the best 
tumor-specific survival in animals with the combination treatment. No evidence of toxic 
alterations upon NW457 treatment was observed in histologic examinations of mouse livers, 
and serum levels of liver enzymes were only marginally elevated suggesting that NW457 
treatment was well-tolerated. 
Different approaches have been developed to find radiosensitizing agents to improve the 
therapeutic width of RT for the treatment of CRCs. Even though neoadjuvant 
radiochemotherapy with 5-fluorouracil or its oral prodrug capecitabine has become a standard 
treatment for advanced rectal cancer, the treatment benefits appear to be limited to local tumor 
control, whereas survival times remain virtually unaffected (Binefa et al., 2014; Sauer et al., 
2012). The majority of clinical evaluations of chemotherapeutics (e.g. oxaliplatin) and 
molecularly targeted drugs (e.g cetuximab, bevacizumab) failed to show benefits in comparison 
to the standard treatment, while to some extent severe side effects were observed (Dipetrillo et 
al., 2012; Eisterer et al., 2014; Ricardi et al., 2013). Very rarely, partial or even complete 
responses were described (Garcia et al., 2015). Since targeted inhibition of HSP90 interferes 
simultaneously with the function of different client proteins involved in maintaining the 
malignant phenotype and the repair of irradiation-induced DNA damage (Lauber et al., 2015; 
Pennisi et al., 2015), it is of high interest to analyze HSP90 inhibitor-mediated sensitization of 
CRCs towards IR. In this regard, a first phase I study has recently been completed. Here, 
multimodal treatment of rectal cancer with the HSP90 inhibitor ganetespib and capecitabine in 
combination with RT (NCT01554969) was examined, but so far no results are available. 
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In the present study, the novel pochoxime-based HSP90 inhibitor NW457 was shown to 
potently sensitize CRC cells towards IR. NW457 treatment led to rapid degradation of the two 
upstream kinases of the DDR, ATM and CHK1, which translated into delayed repair of 
irradiation-induced DNA damage and reduced clonogenic survival of CRC cells. This is in 
accordance with other studies in the same as well as in other cancer entities (Chettiar et al., 
2016; Dote et al., 2006; Ernst et al., 2015; Moran et al., 2008; Spiegelberg et al., 2015; Stingl 
et al., 2010). Interestingly, NW457 treatment interfered with DNA damage repair and 
clonogenic survival independently of the p53 and BAX status. The dispensability of p53 is in 
line with data from another report in colorectal cancer cell lines in which HSP90 inhibitor-
mediated abrogation of irradiation-induced G2 arrest, premature mitosis, and subsequent 
mitotic catastrophe have been suggested as underlying mechanisms (Moran et al., 2008). 
However, p53's role in this scenario is still controversially discussed, and further analyses are 
needed (Fujii et al., 2010; Moran et al., 2008; Shintani et al., 2006).  
In terms of apoptosis induction, NW457 treatment in combination with IR revealed a largely 
synergistic mode of action. Predominantly the intrinsic apoptosis pathway was involved as 
indicated by caspase 9 cleavage and strongly reduced apoptosis levels in BAX-deficient cells. 
This is in accordance with other reports in this cancer entity (Azoitei et al., 2012; He et al., 
2013; He et al., 2014). Induction of apoptosis upon NW457 treatment in combination with 
irradiation only partially required p53, since apoptotic cell death was clearly observed in p53-
deficient cells. This is of high clinical relevance, since TP53 is mutated or lost in approximately 
50% of all CRCs indicating the potential benefit of NW457 treatment in CRCs lacking 
functional p53 (Naccarati et al., 2012). Several attempts have been made to explain p53-
independent induction of apoptosis in response to DNA damage on the molecular level. On the 
one hand, p14ARF that was constitutively upregulated in the p53-deficient cells in the present 
study can stimulate intrinsic apoptosis in a Bcl-2 homologous antagonist/killer (BAK)-
dependent manner and in the absence of p53 and BAX (Hemmati et al., 2006). On the other 
hand, p63 and p73, two close relatives of p53, have been reported to induce intrinsic apoptosis 
by transactivation of promotors of pro-apoptotic genes encoding for BAX, NOXA, and PUMA 
(Cai et al., 2012; Flinterman et al., 2005). Whereas apoptosis induction upon treatment with 
higher concentrations of NW457 was largely BAX-dependent, reduction in clonogenic survival 
by low nanomolar concentrations of NW457 was virtually independent of BAX. Hence, 
different concentrations of NW457 appear to trigger different mechanisms of cell death. 
The in vivo efficacy of HSP90 inhibitor monotherapy has been proven in models of CRC 
(He et al., 2014; Powers et al., 2013). However, studies of the therapeutic efficacy of HSP90 
inhibition in combination with IR so far are limited to xenograft models and other cancer 
entities (Bisht et al., 2003; Bull et al., 2004; Chettiar et al., 2016; Yin et al., 2010; Zaidi et al., 
2012). In these models, the combination treatment has been reported to be superior to the 
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monotherapies as measured by tumor growth control and survival. Our study analyzes for the 
first time HSP90 inhibitor-mediated radiosensitization in a syngeneic murine CRC model. 
HSP90 inhibition with NW457 in combination with irradiation showed significantly improved 
therapeutic efficacy as measured by tumor growth and tumor-specific survival in comparison 
to the monotherapies. It is worth mentioning that the murine CT26 CRC cell line utilized in this 
model carries an activating mutation in the proto-oncogene KRAS as reported for up to 50% of 
all CRCs, thereby strengthening the clinical relevance of this treatment approach (Bazan et al., 
2005). Moreover, NW457, which was developed with special focus on improved water 
solubility, bioavailability, and reduced liver toxicity, showed no evidence of toxic alterations 
in liver histology and only slight increases in serum levels of liver enzymes.  
In summary, this study characterizes HSP90 inhibition by the novel pochoxime-derivative 
NW457 as a promising combined modality approach with RT for the treatment of CRC on the 
basis of its good in vivo efficacy and tolerability. 
My contribution to this study: 
My shared first authorship results from the major contributions I made to the design of this 
study and its experiments. Besides performing a large proportion of the experiments, I 
evaluated, interpreted, and discussed the results. Furthermore, I corrected, discussed, and gave 
scientific input to the manuscript. 
Experimentally, I contributed the following: 
 Measurements of apoptotic and necrotic cell death in different cell lines by flow 
cytometry (Fig. 2E-G, Fig. 4D-I, Suppl. Fig. 4A,B, Suppl. Fig. 5A,C) 
 Western blot analyses of caspase and caspase substrate cleavage and enzymatic 
assays for determination of caspase activity (Fig. 3A,B,D, Fig. 4A) 
 Measurements of liver enzyme serum levels and preparation of mouse livers for 
histopathologic analyses (Fig. 6D,E) 
 Cell cycle analyses (Suppl. Fig., 1G,H) 
5.3 Additional Unpublished Data 
Accumulating evidence suggests that the efficacy of RT relies, apart from the induction of 
DNA damage resulting in cell cycle arrest and cell tumor death, on the induction of specific 
adaptive anti-tumor immune responses that contribute to tumor control (Frey et al., 2014; 
Lauber et al., 2015). This contribution of the immune system appears to be particularly relevant 
in the context of irradiation regimes with high, ablative doses. However, for several cancer 
entities, including CRC, ablative doses cannot be used due to safety concerns. Instead, RT is 
performed using conventionally fractionated (1.8-2 Gy per fraction) or hypofractionated (2.66-
5.0 Gy per fraction) RT strategies (Binefa et al., 2014; Glimelius, 2002). Immunostimulatory 
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effects of these RT regimes are currently under investigation and are controversially discussed 
(Filatenkov et al., 2015; Kulzer et al., 2014). Since HSP90 inhibition has been considered to 
favor anti-tumor immune mechanisms (Alarcon et al., 2012; Lauber et al., 2015), it is of high 
interest whether HSP90 inhibition can enforce anti-tumor immune responses of non-ablative, 
hypofractionated irradiation doses in CRC. Although HSP90 inhibitors have been shown to be 
potent radiosensitizers in CRC models (He et al., 2014; Spiegelberg et al., 2015), the 
immunological potential of HSP90 inhibition-mediated radiosensitization has not been studied 
so far. 
Therefore, this study focused on elucidating the immunogenicity of irradiation-induced 
colorectal cancer cell death with or without additional HSP90 inhibition in the sense of an in 
situ vaccination strategy. The initial steps required for stimulating systemic anti-tumor immune 
responses in this context are characterized by the release of immunostimulatory DAMPs and 
tumor antigens via induction of immunogenic forms of tumor cell death (Chen and Mellman, 
2013; Kroemer et al., 2013). In vitro, high concentrations of NW457 resulted in increased and 
accelerated irradiation-induced apoptosis and subsequent secondary necrosis of human 
HCT116 CRC cells (Figure 6A) (Kinzel et al., 2016). This was accompanied by an augmented 
release of DAMPs, including HMGB1, HSP70, and ATP into the culture supernatants as 
measured by enzyme-linked immunosorbent assay (ELISA) and luciferase assays (Figure 6B). 
Hence, HSP90 inhibition apparently can shift irradiation-induced cell death towards more 
immunogenic forms with increased DAMP release.  
Extracellular DAMPs can stimulate the attraction of monocytes which then can differentiate 
into DCs – the central players in the induction of adaptive anti-tumor immune responses 
(Lauber et al., 2012). In vitro, cell-free supernatants derived from NW457-treated and irradiated 
HCT116 cells potently attracted monocytic THP-1 cells in transwell migration assays (Figure 
6A). To investigate which form of cell death was crucial for the release of monocyte attraction 
signals, different genetic subclones of HCT116 cells were utilized. These subclones showed 
clear differences in the mode of cell death induced by HSP90 inhibition in combination with 
irradiation. Whereas the parental cells (BAX+/+, KRAS+/-) first underwent apoptosis and then 
transited into secondary necrosis, the BAX-deficient subclone displayed limited apoptosis 
induction and very little secondary necrosis (Figure 6C) (Zhang et al., 2000). Interestingly, 
KRAS wildtype cells underwent apoptosis to a comparable extent as the parental cells 
(Shirasawa et al., 1993). However, they did not transit into secondary necrosis. In turn, only 
cell-free supernatants of secondary necrotic HCT116 wildtype cells attracted monocytic cells 
upon combination treatment. No relevant monocyte migration was observed in response to 
supernatants of the other subclones, suggesting that secondary necrosis is essential for the 
release of monocyte attracting DAMPs. This was further confirmed by analyses in the presence 
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or absence of the poly-caspase inhibitor zVAD-fmk and the necroptosis inhibitor necrostatin-
1. Upon addition of zVAD-fmk, induction of apoptosis was virtually abrogated resulting in very 
low levels of subsequent secondary necrosis and no detectable transwell migration of THP-1 
cells (Figure 6D). In contrast, addition of necrostatin-1 affected the induction of secondary 
necrosis or THP-1 cell migration only marginally. Accordingly, secondary necrosis appears to 
be the decisive mode of cell death that is required for the release of monocyte attraction signals 
in this scenario.  
A characterization of the monocyte attraction signals derived from secondary necrotic cells 
upon HSP90 inhibition in combination with irradiation was performed with cell-free 
supernatants of HCT116 cells harvested 48 h after treatment (which revealed the highest 
migratory potential). After subjection of the supernatants to heat-treatment, filtration (MW cut-
off 10 kDA), and enzymatic digestion with apyrase (ATP diphosphohydrolase) or proteinase K 
(serine protease), respectively, the remaining migratory potential was analyzed. ATP (MW = 
507 Da, apyrase-sensitive) and stromal cell-derived factor 1-alpha (SDF-1α) (MW = 11 kDa, 
apyrase-insensitive) served as controls. Our data indicate that the majority of attraction signals 
are heat-stable, smaller than 10 kDa, and sensitive to apyrase treatment. Hence, the factors are 
apparently nucleotides (Figure 7A). Time-lapse video microscopy with 2D chemotaxis assay 
slides were performed to characterize the nature of the migratory response: chemotaxis 
(directional movement of cells towards a stimulus) or chemokinesis (non-directional movement 
in response towards a stimulus). As shown in Figure 7B, supernatants of HSP90 inhibitor-
Figure 6 HSP90 inhibition shifts ionizing radiation-induced colorectal cancer cell 
death towards more immunogenic forms with increased DAMP release.  
(A) Induction of apoptosis and necrosis, and transwell migration of THP-1 cells towards 
cell-free culture supernatants of irradiated and NW457-treated HCT116 cells. Cells were 
irradiated at 0-5 Gy and concomitantly treated with 0-625 nM NW457. At the indicated 
time points, induction of apoptosis and necrosis was assessed by flow cytometric 
measurements of subG1 nuclei or propidium iodide exclusion staining, respectively. 
Harvested cell-free supernatants were subjected to transwell migration assays with 
monocytic THP-1 cells. Means ± s.d. of quadruplicates are shown. (B) Time-dependent 
release of HMGB1, HSP70, and ATP from irradiated and NW457-treated HCT116 cells. 
Cells were treated as in (A). In cell-free supernatants, HMGB1 and HSP70 were 
quantified by ELISA, and ATP was measured by luciferase assay. Means ± s.d. of 
triplicates are depicted. (C) Induction of apoptosis, necrosis, and transwell migration of 
THP-1 cells towards cell-free culture supernatants of irradiated and NW457-treated 
HCT116 wildtype cells (heterozygous KRAS mutation) and the BAX-/- subclone or the 
wildtype KRAS subclone. Cells were left untreated or irradiated at 5 Gy and treated with 
625 nM NW457. At the indicated time points, apoptosis and necrosis induction as well 
as transwell migration of THP-1 cells towards cell-free supernatants were analyzed as in 
(A). Means ± s.d. of quadruplicates are shown. (D) Relevance of secondary necrosis or 
necroptosis for transwell migration of THP-1 cells. Induction of apoptosis and necrosis, 
and transwell migration of THP-1 cells were measured as in (A) in the presence or 
absence of the poly-caspase inhibitor zVAD-fmk and the necroptosis inhibitor 
necrostatin-1. Means ± s.d. of quadruplicates are displayed. 
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treated HCT116 cells induced chemokinesis rather than chemotaxis. This was observed already 
with NW457 monotherapy, and it was even more enhanced when cells were additionally 
irradiated. For comparison, purified ATP was used as a chemokinetic stimulus, and WKYMVm 
(an agonist of formyl-peptide receptors 1, 2, and 3) served as prototypical chemotactic stimulus. 
Digestion of the supernatants with apyrase again confirmed the importance of nucleotides in 
the migratory response (Figure 7C). Therefore, it can be concluded that NW457 treatment in 
combination with irradiation induces the release of apyrase-sensitive nucleotides from 
secondary necrotic CRC cells, which are able to stimulate monocyte migration in vitro. 
The question that arises at this point is whether the non-directional migratory response of 
monocytes observed in vitro can be converted into directional recruitment of monocytes in vivo. 
In a first approach to address this question, the recruitment of leukocyte subsets by supernatants 
of untreated or combinedly treated HCT116 cells was examined in two in vivo surrogate 
models. In the peritonitis model, intraperitoneal injection of conditioned supernatants from 
combinedly treated HCT116 cells stimulated infiltration of the following myeloid leukocyte 
subsets to a significantly stronger extent than conditioned supernatants from untreated control 
cells: Inflammatory monocytes (Gr-1hiF4/80hi & Gr-1hiF4/80int), macrophage-like cells (Gr-
1lowF4/80hi), and neutrophils (Gr-1hiF4/80low) (Figure 7D). In analogy, significantly increased 
adhesion and extravasation of leukocytes and CX3C chemokine receptor 1 (CX3CR1)-
expressing monocytic cells from postcapillary venules were observed in the cremaster model 
upon intrascrotal injection of conditioned supernatants from combinedly treated HCT116 cells 
(Figure 7E). Inflammatory monocytes express low levels and resident monocytes high levels 
of CX3CR1 (Soehnlein et al., 2009). CX3CR1-expressing DCs were excluded from the 
analyses on the basis of their characteristic stellate morphology.  
Encouraged by these positive in vivo results, intratumoral recruitment of different leukocyte 
subsets was examined in a heterotopic, syngeneic colorectal tumor model upon irradiation 
and/or HSP90 inhibitor treatment. Murine CT26 CRC cells were subcutaneously inoculated 
into the right flanks of Balb/c mice. Tumors were allowed to grow for 7 days and tumor-bearing 
mice were randomly distributed into four treatment groups: Vehicle (dimethyl sulfoxide 
(DMSO)) only, 2x 5 Gy + vehicle, NW457 only, and 2x 5 Gy + NW457. 100 mg/kg of NW457 
or DMSO were administered intraperitoneally on days 7 and 10 after tumor implantation. Local 
irradiation was performed on days 8 and 11. Mice were sacrificed for analysis of intratumoral 
leukocyte infiltration on day 14. Tumor volume measurements revealed exponential tumor 
growth in the vehicle controls, whereas NW457 slightly and irradiation strongly delayed tumor 
growth (Figure 7F). Importantly, the best tumor growth control was observed in mice receiving 
the combination treatment, thus confirming our previous observations (Kinzel et al., 2016). Our 
flow cytometry measurements show that irradiation stimulated a strong intratumoral 
accumulation of CD45+ leukocytes that was even increased by additional HSP90 inhibition. 
SUMMARY AND DISCUSSION OF PUBLICATIONS 
36 
SUMMARY AND DISCUSSION OF PUBLICATIONS 
37 
 
Figure 7 Secondary necrotic colorectal cancer cells release DAMPs that stimulate 
chemokinesis of monocytes in vitro and induce recruitment of monocytes and DCs in vivo. 
(A) Characterization of monocyte attraction signals. HCT116 cells were treated with 5 Gy and 
625 nM NW457 and incubated for 48 h. Migratory capacity of ultracentrifugated (42000 G, 
143 min, 4°C) cell- and apoptotic microbleb-free supernatants was determined after heat-
treatment, ultrafiltration (MW cut-off 10 kDA), or enzymatic digestion for 30 min at 30°C with 
active and heat-inactivated proteinase K (3 U/ml) or apyrase (50 mU/ml), respectively, in 
transwell migration assays with THP-1 cells. Culture media supplemented with ATP (200 nM) 
and SDF-1α (200 ng/ml) severed as controls. The percentage of transmigrated THP-1 cells was 
normalized on the untreated samples or control stimuli. Means + s.d. from quadruplicates are 
shown. (B) Induction of chemotaxis and chemokinesis in primary human monocytes. 
Conditioned supernatants of HCT116 cells were generated as in (A), and stimulation of 
chemotaxis and chemokinesis in primary human monocytes was analyzed by live cell tracking 
in 2D-chemotaxis chambers for 3 h (analysis window 10 min - 160 min). ATP (1 µM) and 
WKYMVm (1 µg/ml) served for comparison. Trajectory paths of 40 randomly picked single 
cells and resulting centers of mass (filled blue circles) are displayed. (C) Characterization of 
chemokinesis inducing factors. Conditioned supernatants of HCT116 cells were harvested as 
in (B) and were digested for 30 min at 30°C with active or heat-inactivated apyrase (50 mU/ml). 
Chemokinesis was analyzed as in (B) with purified ATP (1 µM) as a control. (D) Recruitment 
of myeloid leukocyte subsets in the peritonitis model. Conditioned supernatants harvested as in 
(B) were intraperitoneally injected into C57BL/6 mice. After 6 h of stimulation, myeloid 
leukocytes (CD45+ CD11b+ cells) recruited into the peritoneum were characterized by flow 
cytometry. Representative plots of two mice are shown (left panel). Quantification of recruited 
leukocytes: Inflammatory monocytes (Gr-1hiF4/80hi, Gr-1hiF4/80int), macrophage-like cells 
(Gr-1lowF4/80hi, Gr-1lowF4/80int, Gr-1lowF4/80low), and neutrophils (Gr-1hiF4/80low) (right 
panel). Means + s.e.m. are shown (n=4 per group). Asterisks indicate p<0.05 as calculated by 
unpaired Student’s t-test to supernatants from untreated control cells. (E) Extravasation of 
leukocytes in the cremaster model. Conditioned supernatants harvested as in (B) were 
intrascrotally injected into CX3CR1GFP/+ mice. After 6 h of stimulation, microscopy images of 
postcapillary venules are shown for two representative mice (left panel), and quantification of 
intravascular rolling, firm adherence, and transmigration of leukocytes and CX3CR1-positive 
monocytic cells is displayed (right panel). Means + s.e.m. are depicted (n=6 per group). 
Asterisks indicate p<0.05 as determined by unpaired Student’s t-test to supernatants from 
untreated control cells. (F) Analysis of intratumoral recruitment of leukocytes in a syngeneic, 
heterotopic mouse model. 1.2x 106 murine CT26 CRC cells were subcutaneously inoculated 
into the right flanks of Balb/c mice and allowed to grow for 7 days. Mice were randomly 
distributed into four treatment groups (n=5 per each treatment group): Vehicle (DMSO) only, 
2x 5 Gy + vehicle, NW457 only, and 2x 5 Gy + NW457. 100 mg/kg of NW457 or DMSO were 
administered intraperitoneally on days 7 and 10 (red arrowheads), and local irradiation was 
performed on days 8 and 11 (black arrowheads). On day 14, mice were sacrificed and tumors 
were explanted for flow cytometric analysis of leukocyte infiltration. Tumor volumes are 
displayed as percentage of the respective starting volume on day 7 (left panel). Means ± s.e.m 
are depicted and two-way ANOVA was used for overall comparison of the curves. Flow 
cytometric data of intratumoral leukocyte subsets are shown as the percentage of all cells 
following doublet exclusion (right panel). Single cell suspensions of the tumors were stained 
against surface markers of leukocytes for quantification of the following subsets: Leukocytes 
(CD45+), all monocytes, inflammatory monocytes (Ly-6Chi), resident/maturing monocytes (Ly-
6Clow), myeloid DCs (F4/80+MHC II (I-A/I-E)hi), macrophages (Ly-6G-F4/80+), and 
neutrophils (Ly-6G+F4/80low). Means + s.e.m. are depicted, and asterisks indicate p<0.05 as 
calculated by unpaired Student’s t-test to the vehicle controls. 
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Among the CD45+CD11b+ myeloid leukocytes, inflammatory monocytes (lymphocyte antigen 
(Ly)-6Chi) were the dominant population followed by Ly-6Clo monocytes, which either can be 
resident monocytes or recruited monocytes in the process of differentiation. Importantly, 
enhanced intratumoral infiltration of Ly-6Chi monocytes was already observed upon irradiation 
alone, but only after additional HSP90 inhibition statistical significance was reached. 
Interestingly, intratumoral numbers of Ly-6Clo monocytes and myeloid DCs (mDCs) 
expressing MHC II (I-A/I-E) showed basically the same trend although the absolute numbers 
were much lower. Hence, HSP90 inhibition obviously can improve irradiation-mediated tumor 
control accompanied by enhanced intratumoral infiltration of leukocytes – in particular Ly-6Chi 
and Ly-6Clo monocytes as well as mDCs. 
Tumor infiltrating immune cells are known to affect the clinical outcome of CRC. In this 
regard, T cell infiltration into tumors has been reported as a biomarker for the treatment 
response, which led to the development of a predictive 'immunoscore' (Perez-Ruiz and 
Berraondo, 2016). Therefore, therapeutic strategies with the aim of enhancing the 
immunological potential of RT in CRC are of special interest (Derer et al., 2015). One 
mechanism how anti-tumor therapies can elicit specific adaptive anti-tumor immune responses 
is the induction of immunogenic forms of cell death with the concomitant release of DAMPs 
(Bezu et al., 2015; Galluzzi et al., 2015). The present study demonstrates for the first time that 
the novel HSP90 inhibitor NW457 can shift the form of irradiation-induced cell death towards 
more immunogenic secondary necrosis with concurrent release of DAMPs leading to attraction 
of monocytes in vitro and in vivo. Furthermore, control of tumor growth upon NW457 treatment 
in combination with irradiation was accompanied by increased intratumoral levels of 
leukocytes, in particular monocytes and mDCs. 
Tumor cells undergoing therapy-induced apoptosis may be insufficiently cleared resulting 
in increased secondary necrosis. This happens especially when the load of dying cells is too 
high and overwhelms the phagocytic compartment. In contrast to apoptosis, post-apoptotic, 
secondary necrosis is considered as an immunogenic form of cell death. Due to the rupture of 
the plasma membrane, several immunogenic DAMPs are released and can contribute to the 
stimulation of anti-tumor immune responses (Garg et al., 2013; Silva, 2010). In the present 
study, several DAMPs were observed to be liberated upon HSP90 inhibition in combination 
with irradiation. For instance, HMGB1, HSP70, and ATP were released from dying colorectal 
cancer cells upon the combined treatment in a time-dependent manner and in parallel to the 
onset of secondary necrosis (data not shown). Extracellular DAMPs may promote tumor 
immunogenicity potentially resulting in the stimulation of systemic anti-tumor immune 
responses (Deloch et al., 2016; Garg et al., 2015). For instance, the DNA chaperoning protein 
HMGB1 binds – among others – to TLR-4 on DCs and promotes processing and cross-
presentation of tumor-associated antigens to T cells, thereby mediating T cell activation 
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(Apetoh et al., 2007; Tesniere et al., 2008). HSP70 has a dual role in cancer biology. The 
intracellular chaperoning function of HSP70 promotes tumor progression by its anti-apoptotic 
properties. Membrane-bound and extracellular HSP70, in contrast, link innate and adaptive 
immune responses by carrying immunogenic tumor-derived peptides and by directly activating 
immune cells as a natural immunogen, thereby promoting maturation of DCs (Joly et al., 2010; 
Shevtsov and Multhoff, 2016). ATP released upon anti-cancer therapy binds to purinergic P2X7 
receptors on DCs and mediates DC activation via the inflammasome. This promotes the 
secretion of the pro-inflammatory interleukin (IL)-1β that is required for the efficient priming 
of tumor-specific IFN-γ producing CD8+ T cells (Aymeric et al., 2010; Ghiringhelli et al., 
2009).  
IR can stimulate immunogenic forms of cell death and consequently induce the release of 
DAMPs, but this clearly depends on the RT regime applied and intrinsic characteristics of the 
tumor cells (Demaria and Formenti, 2012; Formenti and Demaria, 2013). Therefore, different 
approaches have been utilized to boost the immunogenic potential of irradiation-induced cell 
death upon treatment with moderate doses of 5 Gy in other colorectal cancer models. Addition 
of chemotherapeutics has been observed to shift irradiation-induced colorectal cancer cell death 
towards higher levels of apoptosis, necrosis, and possibly also necroptosis accompanied by the 
release of HMGB1 and HSP70 and, in turn, maturation of DCs in vitro (Frey et al., 2012). 
Hyperthermia in combination with RT can enforce the induction of necrotic cell death and the 
release of HMGB1 and HSP70 (Mantel et al., 2010; Schildkopf et al., 2010; Schildkopf et al., 
2011). In this context, HSP70 was identified as key driver of DC maturation and expression of 
the homing receptor CCR7. Interestingly, hyperthermia shares a common feature with HSP90 
inhibition: The induction of the heat shock response (Lauber et al., 2015). Thus, it is tempting 
to speculate that HSP90 inhibition may induce similar immunomodulatory effects that enhance 
the immunogenicity of irradiation-induced CRC cell death, especially in regard to the observed 
release of HMGB1 and HSP70 from secondary necrotic tumor cells upon combined treatment.  
Circulating leukocytes have to infiltrate the tumor in order to contribute to tumor control. It 
has been reported that the intratumoral recruitment of APCs originating from inflammatory 
monocytes of the peripheral blood (CD45+CD11b+Gr-1hi) and their production of type I IFNs 
is of vital importance for the treatment efficacy of RT with ablative doses (Burnette et al., 2011; 
Lim et al., 2014). In our study, addition of NW457 enforced the capacity of CRC cells that were 
irradiated with non-ablative doses of 5 Gy to attract monocytes in vitro. In this scenario, 
secondary necrosis, which was only observed in HCT116 wildtype cells carrying a 
heterozygous KRAS mutation, was of essential importance. Mutant KRAS appears to be 
involved in the induction of this form of cell death and/or the associated release of DAMPs. 
Hence, secondary necrosis may not be as accidental as it currently still is considered to be.  
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Central regulators of monocyte attraction were identified as apyrase-sensitive nucleotides 
derived from secondary necrotic colorectal cancer cells upon HSP90 inhibition in combination 
with RT. Several studies have already demonstrated a role of dying cell-derived nucleotides in 
the recruitment of monocytes, macrophages, and DCs via ligation of P2Y purinoceptor 2 
(P2RY2) (Elliott et al., 2009; Ghiringhelli et al., 2009; Ma et al., 2013a). Whether nucleotides 
act as chemoattractants for immune cells per se or rather function as auto- and/or paracrine 
amplifiers of other chemotactic stimuli is currently under discussion (Hennel et al., 2014; Isfort 
et al., 2011; Kronlage et al., 2010). In the present study, chemokinesis but not chemotaxis was 
observed in vitro. However, cell-free supernatants of irradiated and NW457-treated HCT116 
cells were well able to stimulate recruitment of neutrophils and/or monocytic cells subsets in 
the peritonitis and the cremaster model in vivo. An interesting question is how the chemokinetic 
signals can be converted into directional recruitment of leukocytes in vivo. In models of laser 
injury, this conversion was reported to be facilitated by upregulation of adhesion molecules and 
inflammatory cytokines on endothelial cells and pericytes, and it is feasible to assume that 
similar mechanisms might also be functional in our model (McDonald et al., 2010; Pittman and 
Kubes, 2013; Stark et al., 2013). Additionally, the initial wave of recruited neutrophils that 
appears approximately 6 h after intraperitoneal injection of supernatants from combinedly 
treated colorectal cancer cells may contribute to monocyte recruitment in a second wave, since 
neutrophil-mediated monocyte recruitment to sites of sterile inflammation has been described 
(Soehnlein et al., 2009).  
In our syngeneic, heterotopic colorectal tumor model, NW457 treatment in combination with 
irradiation led to significantly increased intratumoral numbers of inflammatory monocytes 
(CD11b+Ly-6Chi) and mDCs (F4/80+MHC II (I-A/I-E)hi) 7 days after treatment begin. Of note, 
this was accompanied by the strongest attenuation of tumor growth control, and further studies 
have to elucidate how far this is causally connected. Intratumoral inflammatory monocytes may 
be of special importance for improving irradiation-mediated tumor control, since inflammatory 
monocytes can differentiate into monocyte-derived DCs, which can activate adaptive immune 
responses as mDCs (Shi and Pamer, 2011). Recruitment of inflammatory monocytic cells has 
already been reported as a critical step in anti-tumor therapy with agents inducing immunogenic 
forms of cell death. Upon anthracycline treatment, nucleotides derived from dying tumor cells 
stimulated intratumoral recruitment of CD11c+CD11b+Ly-6Chi monocytic cells as well as their 
activation, differentiation, and intratumoral survival. These monocytic cells can differentiate 
into potent APCs, which engulf dying cancer cells and present tumor antigens to T cells (Ma et 
al., 2013a; Ma et al., 2013b).  
Collectively, our results suggests that HSP90 inhibition can enforce the immunogenicity of 
irradiation-induced CRC cell death via stimulation of immunogenic forms of cell death and 
attraction of monocytes in vitro and in vivo. Further studies have to elucidate if and to which 
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extent this enhanced tumor immunogenicity together with the recruitment of distinct immune 
cell subpopulations contribute to local and systemic tumor control in this scenario.  
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